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ABSTRACT 
Orthotopic liver transplantation is the treatment of choice 
for many patients with end-stage liver disease. Despite 
advances in immunosuppression, acute rejection remains common 
(up to 70%) and results in significant patient morbidity. 
It is frequently difficult to distinguish abnormal liver 
function due to rejection from that due to infection, biliary 
obstruction or ischaemic injury without performing invasive 
procedures such as a liver biopsy or angiography which may be 
Clinically, the diagnosis of rejection is usually 
once the immunological process is already 
hazardous. 
made late, 
established. 
In this study, we evaluated standard biochemical parameters 
and cytokine concentrations (IL-1, IL-6 and TNF-alpha) in 
serial samples of bile obtained post-operatively via the T-
tubes of patients following orthotopic liver transplantation 
in order to determine whether there are any biochemical or 
immunological pointers to the early diagnosis of rejection 
which would enable earlier administration of appropriate anti-
rejection therapy. 
Biliary cytokines did not prove to be useful and reliable 
markers of early rejection. Serial measurement of biliary 
bilirubin levels showed an early and significant decrease a 
few days prior to rejection, and were a more sensitive marker 
of graft function than serum bilirubin levels. 
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CHAPTER ONE 
Orthotopic Liver Transplantation At Groote Schuur Hospital 
In the last decade, liver transplantation has evolved from an 
experimental procedure to its present status of being the 
treatment of choice for many patients with end-stage liver 
disease. The first human liver transplant was performed by 
T.E. Starzl in Denver in 1963. Initially, results were poor 
with only a few patients surviving for any significant length 
of time. However,with improved surgical techniques, intensive 
care and advances in immunosuppression, there has been a 
marked improvement in the results of liver transplantation. 
In June 1983, a Consensus Development Conference of the 
National Institutes of Health (USA) concluded that liver 
transplantation was no longer an experimental procedure but 
had become a therapeutic option1 • 
Chronic liver disease accounts for approximately 5% of all 
admissions to the medical wards of South African hospitals. 
The medical management of complications related to liver 
failure is expensive and remains largely palliative. Most 
patients remain debilitated and unable to work. Orthotopic 
liver transplantation offers the patient the chance of cure 
and complete rehabilitation2 • 3 • The quality of life for most 
survivors of liver transplantation appears similar to that of 
the normal population4 . 
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The liver transplantation programme was initiated at Groote 
Schuur Hospital in October 1988 and to date, 11 orthotopic 
liver transplantations have been performed. All patients 
referred to the MRC/UCT Liver Research Centre were assessed 
according to standard criteria for inclusion in or exclusion 
from the transplantation programme. 
1.1 SELECTION PROTOCOL 
Selection of suitable patients and the timing of 
transplantation are important factors in the initiation of a 
transplantation programme5 •6 • 
The indications for orthotopic liver transplantation2 include 
chronic advanced liver disease, metabolic liver disease, 
hepatic malignancy and fulminant liver failure. Chronic liver 
disease may be subdivided into those conditions which are 
predominantly cholestatic (primary biliary cirrhosis, primary 
sclerosing cholangi tis and biliary atresia) and those which 
predominantly affect the liver parenchyma. The latter include 
post-necrotic viral cirrhosis, chronic drug induced liver 
disease, alcoholic liver disease and autoimmune chronic 
active hepatitis. Patients with Budd-Chiari syndrome may also 
benefit from liver transplantation. Liver transplantation for 
hepatocellular carcinoma (HCC) is controversial because of 
the high recurrence rate. Cholangiocarcinoma is an absolute 
contraindication. However, other tumours such as the 
fibrolamellar variant and haemangioendotheliomas behave less 
3 
aggressively. Liver transplantation for fulminant liver 
failure is also controversial. Most of these patients rapidly 
deteriorate clinically and die before a suitable donor 
becomes available. 
Various inborn errors of metabolism are now treatable by 
liver transplantation. These include processes where the 
liver is severely damaged (Wilson's disease, alpha-! 
antitrypsin deficiency) or those where the liver is 
morphologically normal but contains a metabolic defect 
damaging another system (familial hypercholesterolaemia). 
The timing of transplantation is difficult. Procrastination 
may allow a patient's condition to deteriorate to the extent 
that life support systems are required2 • This may often 
preclude transplantation. Catastrophic complications are not 
always predictable and there is a tendency to underestimate 
the severity of the liver disease. Factors such as rapidly 
progressive jaundice, intractable ascites, spontaneous 
encephalopathy, repeated variceal bleeds and recurrent 
septicaemia are all indications for urgent transplantations. 
Other factors indicating the need for transplantation include 
coagulopathy with an INR > 2 unresponsive to vitamin K in 
chronic liver disease, estimated life expectancy of one year 
or less, or distressing symptoms such as intractable pruritus 
resulting in poor quality of life7 • 
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1.2 CONTRAINDICATIONS TO TRANSPLANTATION 
Contraindications may be either absolute or relative and are 
continually being revised2 • 7 . 
1.2.1 Absolute contraindications include: 
1) Severe cardiorespiratory disease 
2) Hypoxaemia (controversial) 
3) Active biliary sepsis 
4) Uncontrolled extrahepatic bacterial or fungal infections 
5) AIDS 
6) Metastatic liver disease 
7) Extrahepatic malignancy 
8) Active substance abuse or alcoholism 
1.2.2 Relative contraindications include: 
1) Portal vein thrombosis 
2) Age greater than sixty years 
3) Previous extensive hepatobiliary surgery 
4) Active hepatitis B viral replication or Delta hepatitis 
virus infection 
5) Advanced chronic renal disease except if renal 
transplantation is concurrently planned 
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1.3 PROCUREMENT AND OPERATIVE PROCEDURE 
Procurement of livers for orthotopic transplantation is 
usually part of a multiple organ procurement programme. The 
most frequent combination at Groote Schuur Hospital is liver 
and kidneys, then liver, kidneys and heart and lastly liver, 
kidneys and heart-lungs. 
The use of the Wisconsin preservation solution now enables 
graft storage for up to 12-24 hours, thus enabling liver 
transplantation to be performed as an elective procedure. 
In orthotopic liver transplantation, the diseased native 
organ is removed and replaced with the new donor liver in the 
most anatomically normal way possible. The technical aspects 
of the transplant procedure have undergone major refinements 
over the years and have been described in detail elsewhere8 • 
The introduction of the extra-corporeal veno-venous bypass in 
1983 to decompress both splanchnic and systemic venous 
circulations has been an important refinement in surgical 
technique. Reconstruction of the biliary tract has become 
standardised and can be done either by connecting the donor 
and recipient common ducts end-to-end over a T-tube or the 
common duct of the donor is anastomosed to a jejunal limb in 
a Roux-en-Y anastomosis. 
Figure 1.1: 
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At orthotopic liver transplantation: T-tube in 
common bile duct with external drainage. 
1.4 IMMUNOSUPPRESSION AND ANTIBIOTIC THERAPY 
The introduction of the immunosuppressive agent cyclosporine 
in the late 1970s resulted in significant improvements in the 
results of solid organ transplantation. Currently, most 
patients receive a combination of steroids, cyclosporine and 
azathioprine as immunosuppression following transplantation. 
Intravenous cyclosporine has significant nephrotoxic 
properties. At Groote Schuur Hospital, we do not routinely 
use this drug immediately post-operatively until the patients 
' 
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can take oral medication. OKT3, a monoclonal antibody is used 
'prophylactically' for the first 5-7 days in place of 
intravenous cyclosporine. We do not have experience with 
FK506 and other monoclonal or polyclonal antilymphocyte 
antibodies. Rejection is treated by pulsing with medrol in as 
low a dose as possible. 
All our patients receive routine prophylactic systemic 
antibiotics in the form of ampicillin or vancomycin and a 
cephalosporin on induction and at the time of biliary 
anastomosis. We do not routinely administer selective bowel 
decontamination therapy. Specific bacterial infections are 
treated with specific antibiotic therapy. All patients 
receive oral anti-fungal agents including nystatin drops and 
amphotericin lozenges. Patients also receive prophylactic 
cotrimoxazole 1 tablet bd for two days of the week for at 
least 90 days against pneumocystis infections. Acyclovir is 
also given prophylactically, initially intravenously and then 
orally for 10-14 days post-operatively. 
1.5 PATIENT DATA 
Eleven patients have undergone orthotopic liver transplant-
ation at Groote Schuur Hospital since October 1988. They 
include 6 males and 5 females and their ages range between 
21-56 years. Indications for liver transplantation included 
chronic active hepatitis progressing to cirrhosis (5); 
biliary cirrhosis ( 1); sclerosing cholangi tis ( 2); alpha-! 
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antitrypsin deficiency (l); haemangioendothelioma (1) and 
cryptogenic cirrhosis ( 1). All patients with chronic liver 
disease had experienced at least one major complication 
relating to liver disease. These included intractable 
ascites, uncontrolled variceal bleeding, encephalopathy, 
recurrent bacterial peritonitis and septicaemia ( See Table 
1.1). 
TABLE 1.1 PATIENT DATA 
Age Sex Diagnosis Child's 
Stage* 
OLTx 1 48 F Autoimmune chronic active C 
hepatitis 
OLTx 2 42 M Post-necrotic cirrhosis C 
OLTx 3 36 F Biliary cirrhosis B 
OLTx 4 21 M Chronic active hepatitis (HBV) B 
OLTx 5 56 M Chronic active hepatitis C 
OLTx 6 39 F Haemangioendothelioma A 
OLTx 7 36 M Sclerosing cholangitis B 
OLTx 8 44 F Chronic active hepatitis(?HBV) C 
OLTx 9 25 M Alpha-1 antitrypsin deficiency C 
OLTx 10 30 F Sclerosing cholangitis B 
OLTx 11 47 M Cryptogenic cirrhosis C 
* Modified Child-Pugh classification Child C.G. III, 
Turcotte J. 1965. In: Child C.G. III (ed). The liver and 
portal hypertension. Philadelphia: W.B. Saunders Co. 
Post-operative complications were mainly of a minor nature 
and included right lower lobe consolidation and effusions, 
seromas at sites of veno-venous bypass and one left medial 
cutaneous nerve palsy. More serious complications have 
included severe acute rejection (OLTx 2 and 5), acute tubular 
necrosis requiring dialysis (OLTx 2), delayed graft function 
(OLTx 7) which improved on conservative medical therapy, and 
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severe ischaemic injury with subsequent biliary strictures 
requiring revision of the biliary tract anastomosis ( OLTx 
11). One patient (OLTx 9) died on the eleventh day post-
operatively with complications of a bleeding oesophageal 
ulcer, shock and candidaemia. Four patients ( OLTx 3, 6, 8, 
11) developed symptomatic cytomegalovirus infection. In two 
cases (OLTx 6, 8), this was mild and responded to a reduction 
in immunosuppressive therapy, but two patients (OLTx 3, 11) 
required treatment with specific anti-viral therapy 
(gancyclovir). One patient (OLTx 7) developed a late distal 
biliary stricture and has subsequently had a 
choledochojejunostomy performed 6 months post 
transplantation. At present, 10 patients are alive and well 
2-32 months following transplantation and most have returned 
to work. 
The post-operative period may be complicated by the 
development of infections (bacterial, viral or fungal), 
rejection, biliary obstruction and the consequences of 
ischaemic injury. As each of these complications requires 
specific therapy, it is important to make the correct 
diagnosis in order to institute appropriate therapy. Despite 
recent advances in immunosuppression, acute rejection is 
common and may result in significant patient morbidity. It is 
often difficult to distinguish abnormal liver function due to 
rejection from that due to infection, biliary obstruction or 
ischaemic injury without performing invasive procedures such 
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as liver biopsy or angiography. These invasive procedures are 
not without risk especially if there is an associated 
coagulopathy and the histology may often only show non-
specific early changes. 
Clinically, the diagnosis of rejection is usually made late 
and depends on the presence of progressive deterioration in 
liver function. The patient may experience fever, 
leukocytosis, graft tenderness and a change in the colour or 
quantity of bile. This is accompanied by a rise in serum 
bilirubin and parameters of liver injury as well as acute 
phase proteins and increased serum neopterin. These features 
imply an established immunological process and it is usually 
at this stage that the immunosuppressive therapy is boosted 
to combat acute rejection. 
The cytokines, interleukin-1 (IL-1), interleukin-6 (IL-6) and 
tumour necrosis factor-alpha (TNF-alpha) are pluri-potential 
cytokines which mediate 
phase reactions 9 , lo, 11. 
mononuclear phagocytes 
immunological responses 
They are produced by 
which are central to 
and acute 
activated 
cellular 
rejection processes. Urinary and serum IL-6 levels have been 
found to be high following surgery as part of the acute phase 
response and have been noted to be particularly elevated 
following episodes of renal transplant rejection12 . 
Soluble interleukin-2 receptors have been shown to be 
elevated in the serum and bile13 •14 of liver transplant 
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patients at the time of rejection. The biliary levels IL-2R 
were more sensitive and specific than the serum levels for 
rejection14 . T cell activation is associated with an increase 
in the expression of interleukin-2 receptors and this 
expression is closely regulated by the cytokines IL-1, TNF-
alpha and IL-6. Measurement of these cytokines, particularly 
in bile, may provide a sensitive marker for early rejection. 
Cholestasis occurs as a result of liver injury and rejection 
processes. Thus alterations in the biliary constituents as a 
result of liver injury due to rejection may be detectable 
prior to changes in the serum. Bile secretion is used as an 
index of hepatic recovery following liver transplantation. 
The absence of bile production following graft reperfusion is 
often an ominous sign and may be associated with primary 
graft failure17 . Bile flow and bile salt secretion following 
liver transplantation has been measured15 , other studies have 
looked at lipid composition16 , while others have looked at 
water and electrolyte secretion following transplantation17 . 
However, no-one has performed serial measurements of biliary 
biochemical parameters and correlated possible changes in 
these parameters with the development of rejection. 
In this study we have evaluated standard biochemical 
parameters and cytokine concentrations (IL-1, IL-6 and TNF-
alpha) in serial samples of bile obtained post-operatively 
via the T-tubes of patients following orthotopic liver 
transplantation in order to determine whether there are any 
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biochemical or immunological pointers to the early diagnosis 
of rejection which would enable earlier administration of 
appropriate anti-rejection therapy. 
CHAPTER TWO 
Immunological Reactions in Orthotoplc Liver Transplantation 
2.1 REJECTION 
Despite recent advances in immunosuppression, acute 
rejection remains common and results in significant patient 
morbidity. It is important to recognise rejection as soon as 
possible so that appropriate immunosuppressive therapy can 
be instituted. It is vital that the diagnosis of rejection 
is correct. The unnecessary administration of large doses of 
steroids or anti-lymphocyte preparations may be extremely 
deleterious with the consequent failure of wound healing and 
the development of infections. 
Acute rejection seldom occurs before the 4th day post 
transplantation and is more frequently seen between the 4th 
and 10th day. It is uncommon after 2 months, unless the 
patient has been inadequately immunosuppressed or has had a 
concurrent infection necessitating a reduction in 
immunosuppressive therapy. 
The patient may experience fever, malaise, graft tenderness 
associated with lymphocytosis, eosinophilia together with a 
rise in bilirubin, alkaline phosphatase and transaminase 
levels. 
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However, none of the clinical signs and symptoms or the 
biochemistry are specific for rejection. Other non-
immunological causes for early hepatic dysfunction must be 
systematically excluded. The differential diagnosis includes 
biliary obstruction, suboptimal revascularisation, viral or 
bacterial infections and drug toxicity. Frequently invasive 
procedures such as a liver biopsy are required to establish 
the diagnosis of rejection. 
protocol biopsies are taken, 
rejection is up to 77% 18 • 
2.1.1 Pathology 
a) Acute Rejection 
In centres where regular 
the incidence of acute 
Histological diagnosis of acute cellular rejection depends 
on the presence of a predominantly mononuclear inflammatory 
cell infiltrate in the portral areas associated with 
evidence 
infiltrate 
of 
lymphocytes, 
some parenchymal damage. 
consists of a mixture of 
The inflammatory 
large blastic 
plasma cells, macrophages, eosinophils, 
neutrophils and dendritic cells. 
The infiltrate accumulates in the interstitium of the portal 
tracts and leads to portal expansion. The inflammatory 
infiltrate accumulates beneath hypertrophied portal vein 
endothelial cells and may be adherent to the endothelial 
surface, this appearance is called endothelialitis19 • 
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Similar endothelialitis may be seen in the terminal hepatic 
venules. The endothelial cells may be lifted up by the 
infiltrating cells. Medium-to-large vessel damage with 
arteri tis and associated fibrinoid necrosis and thrombosis 
may occur20 • The portal infiltrate may obscure small bile 
ducts and infiltrate the epithelium which shows a variety of 
abnormalities. Ductular cell hyperplasia and an increase in 
the nuclear to cytoplasmic ratio are the most 
findings. Other degenerative changes in the 
epithelium include subnuclear vacuolisation, 
frequent 
biliary 
nuclear 
pyknosis, eosinophilic degeneration or frank luminal 
disruption20 • The portal mononuclear infiltrate may spill 
over and be associated with periportal hepatocyte necrosis 
and there may be some centrilobular hepatocyte necrosis 
associated with involvement of the central veins 20 •21 • 
Canalicular cholestasis is usual but cellular cholestasis 
involving perivenular cells may also occur18 • Following 
boosted immunosuppression, usually in the form of pulses of 
intravenous medrol, most patients show histological 
recovery, although minor residual portal scarring may 
persist18 • 
Acute cellular rejection may be graded as mild, moderate or 
severe depending on the combination of the degree of 
exuberance of the monuclear portal infiltrate, the extent of 
tissue damage and the presence of arteritis and/or ischaemic 
necrosis 21 • 
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Figure 2.1: Florid cellular rejection. Hepatocellular 
necrosis, endothelial cell damage with mono-
nuclear cell infiltration. 
b) Chronic Rejection 
This usually occurs after 2 months following transplant-
ation. It is characterised by an indolent but progressive 
loss of bile ducts and obliterative arteriopathy20 , 21 • 
Clinically patients become progressively jaundiced with a 
cholestatic liver enzyme pattern. Liver synthetic function 
remains intact until late in the course. Histological 
diagnosis of chronic rejection depends on the loss of small 
bile ducts and portal arteries or arterial mural thickening 
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and hyalinization20 •21 • There may only be a mild-to-moderate 
mononuclear portal infiltrate. The composition of the 
infiltrate differs from that in acute rejection in that it 
contains fewer blastoid lymphocytes, neutrophils and 
eosinophils with a possible increase in plasma cells20 • With 
time, the bile ducts are completely destroyed and replaced 
by fibrous tissue. Portal tract expansion due to fibrosis 
and hyalinization of connective tissue occurs. Lobular 
changes include 
intrasinusoidal foam 
central 
cell 
necrosis of hepatocytes and 
atrophy and sclerosis21 . 
canalicular cholestasis, 
clusters, mild acidophilic 
perivenular hepatocellular 
The obliterative arteriopathy involves the second and third 
order branches of the hepatic artery and is thus often not 
seen on biopsy. The usual pathology is subintimal foam cell 
deposition but an intimal lymphohistiocytic infiltrate 
together with smooth muscle proliferation, disruption of 
elastic lamina and intimal fibrosis may occur. Major bile 
ducts may be involved with epithelial sloughing, focal 
necrosis, mural fibrosis and features of both acute and 
chronic inflammation21 • The histological findings of chronic 
rejection usually correlate well with the presence of a 
cholestatic liver enzyme pattern. Chronic rejection is 
usually unresponsive to increased immunosuppressive therapy. 
Graft failure is progressive and the only effective 
treatment is retransplantation. 
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Figure 2.2: Obliterative arteriopathy with subintimal foam 
cell deposition. 
2.1.2 Pathogenesis 
Rejection is an immune reaction elicited by a genetic 
disparity between the donor and the recipient. It 
demonstrates both specificity and memory and is thought to 
be directed at the major histocompatibility complex (MHC), 
blood group and possibly at tissue specific antigens 
expressed on the surface of graft cells. It involves both 
cellular and humoral mediated immunity. 
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The morphological changes of acute rejection are comparable, 
in terms of the component cells and their relationship to 
small vessels, to the changes seen in cellular rejection of 
renal and other allografts. However, the liver differs from 
other organs in a number of important ways. Antibody 
mediated hyperacute rejection is uncommon even in the 
presence of circulating antibodies against graft 
antigens18 •22 • Also, the liver has the capacity to induce a 
specific immunological unresponsiveness to grafts of other 
organs from the same donor strain18 • 
a) Hyperacute Rejection 
Antibodies present in the recipient circulation prior to 
transplantation directed at antigens expressed on 
endothelial cells of the graft have the potential to cause 
an immediate form of vascularised allograft failure called 
hyperacute rejection. The major blood group isoagglutinins 
and warm T-lymphocytotoxic antibodies can both cause 
hyperacute rejection of kidney and heart grafts. Binding of 
the preformed antibodies to the graft vasculature results in 
complement fixation and activation, endothelial cell damage, 
vasospasm, platelet aggregation, subsequent activation of 
the clotting and fibrinolytic cascades and neutrophilic 
activation. The end result is diffuse intraorgan thrombosis, 
haemorrhagic necrosis and graft failure21 , 32 • 
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Liver allografts tend to be resistant to hyperacute 
rejection. Early graft failure is not usually observed when 
warm T-lymphocytotoxic antibodies are present at the time of 
transplantation. However, when major blood ABO group 
barriers are violated, then early graft failure due to 
haemorrhagic necrosis which is attributed to antibody-
mediated rejection, is more frequently encountered. 
The resistance of the liver to hyperacute rejection may be 
due to a number of factors which include: 
1. Dual afferent blood supply: The liver receives afferent 
blood from both the hepatic artery and the portal vein. 
Compromise of either blood supply results in compensatory 
increased flow in the other and this may thus protect the 
liver from ischaemic injury23. 
2. Sinusoidal network lined with Kupffer cells: The majority 
of the microvasculature is sinusoidal, lined by fenestrated 
endothethial cells which lack an underlying basement 
membrane which plays a role in platelet aggregation. Also 
the Kupffer cells protect the liver by absorbing antibodies, 
immune complexes and platelet aggregates24 . 
3. Secretion of soluble MHC antigens into the circulation: 
Soluble MHC antigens in the circulation may bind to and 
neutralise lymphocytotoxic antibodies thereby preventing 
binding to the endothelial and other graft cells. It has 
been shown that preformed lymphocytoxic antibodies disappear 
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from the serum soon after liver transplantation and that the 
liver protects other grafts eg. kidneys from the same donor 
against hyperacute rejection in highly sensitised 
recipients 21 •25 • This may be due to Kupffer cell absorption 
and/or the neutralisation of the antibodies by solubilised 
antigens 21 • 26 • 
b) Acute Cellular Rejection 
The major histocompatibility complex is localised in humans 
on the short arm of the sixth chromosome and it codes for 
the highly polymorphic glycoprotein HLA antigens18 • 
Class I antigens comprise HLA - A, Band C, each of which 
has a separate locus within the MHC. Their products are 
transmembrane glycoproteins (MW 45 kD) which are associated 
at the cell surface with a smaller 12kD peptide, beta 2 
microglobulin. Class I antigens were said to be expressed on 
the cell surfaces of all nucleated somatic cells18 • However 
the liver shows considerable variability of expression of 
Class I antigens between different cell types. Sinusoidal 
lining cells and bile duct epithelium normally express the 
class I antigen18 •27 •28 and hepatocytes are generally found 
to be negative. Arterial and venous endothelia have been 
found to express Class I antigen27 • 
Class II antigens are encoded by at least three loci i.e. 
DP, DQ and DR. Their gene products include both alpha and 
beta glycoprotein chains with molecular weights of 34 and 28 
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kD respectively. Class II antigens are involved in antigen 
presentation and serve as the primary targets for helper T 
lymphocytes. Class II antigens have a more limited 
distribution and are expressed on monocyte/macrophage series 
whose function is to phagocytose and process foreign 
antigens. The processed foreign antigen is then recognised 
by other immunocompetent cells especially T-helper cells 
together with self HLA Class II antigen. Class II antigens 
are also expressed on B lymphocytes, activated T lymphocytes 
and dendritic cells18,29. 
In the liver, dendritic cells in the portal tracts 
sinusoidal cells and Kupffer cells all express Class II 
antigens28 •29 . Hepatocytes, bile duct 
vascular endothelia of the hepatic 
central venules are usually negative18 . 
epithelium and 
artery, portal 
the 
and 
Changes occur in the expresssion of Class I and Class II 
major histocompatibility antigens by liver parenchymal and 
vascular endothelial cells of liver allografts during 
rejection, but also in grafts damaged by ischaemia, duct 
obstruction and hepatitis 3•30 . Class I antigens become 
expressed on hepatocytes; class II antigens are expressed on 
bile duct epithelium and on vascular endothelium21 . 
Several cellular immune effector pathways have been 
implicated in acute rejection including: 
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(1) delayed type hypersensitivity 
(2) allogeneic cytotoxic T lympholysis 
(3) antibody - dependent cellular cytotoxicity mediated 
through killer cells 
The histological diagnosis of acute cellular rejection 
depends on a predominantly mononuclear cell infiltration 
concentrated in the portal tracts together with oedema and 
some parenchymal necrosis. The bile ducts, veins and 
arteries are most commonly damaged. 
The portal infiltrate consists of an admixture of large 
blastic lymphocytes, smaller lymphocytes, plasma cells, 
macrophages, neutrophils and eosinophils19 • 20 • The T 
lymphocytes have been shown to be the predominant cells. T4 
cells have predominated in some studies whereas TS cells 
have predominated in others18 . Classically, cytotoxic TB 
cells were thought to be the cells which mediated graft 
destruction. It now appears that there is a complex 
interplay between cytotoxic T cells, helper T cells and 
macrophages. Helper T cells are thought to be central in 
rejection responses as they are able to activate cytotoxic 
T-cells, macrophages and B cells18 • Helper T4 cells produce 
lymphokines including IL-2 which stimulate the cytotoxic T 
cells to proliferate and mature into effector cytotoxic T 
cells. 
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Allogeneic MHC antigens are capable of stimulating recipient 
T cells without needing to associate with host MHC antigens. 
Graft cells are capable of eliciting rejection reactions 31 • 
The graft cell expressing foreign MHC Class II antigens may 
stimulate host helper T cells which then induce cytotoxic T 
cells to destroy the target graft cell. T helper cells 
reacting to the graft release lymphokines which stimulate 
macrophages to enter the graft and destroy it31 • In addition 
to the monocyte/macrophage series acting as antigen 
presenting cells, the dendritic cells are also thought to be 
important non-phagocytosing antigen presenting cells (APC). 
The dendritic cells constitutively express MHC Class II 
molecules and are potent stimulators of mixed lymphocyte 
reacti vi ty31 • After liver transplantation, these dendri tic 
cells may leave the graft and enter the draining lymphatic 
system where they are particularly effective in sensitising 
the host31 • 
Thus the relative distribution of Class I and Class II MHC 
antigens in the transplanted liver corresponds to the 
histological appearances of acute rejection with the 
concentration of immunocompetent cells in the portal areas 
and associated with the endothelium of central and hepatic 
venules. 
Frequently there is a concurrent viral and/or bacterial 
infection in these patients which may lead to increased 
expression of MHC antigens and thus increased graft 
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damage18 • 33 • The relative absence of Class I antigen and the 
complete absence of Class II antigen from hepatocytes, the 
main functional uni ts of the liver, may explain why the 
liver appears to be rejected less aggressively than other 
organs and why histologically there is minimal hepatic 
necrosis. Class II antigens are strongly expressed in the 
Kupffer and dendritic cells of the graft and these donor 
cells are replaced by cells of host origin within 4 months 
of transplantation18 • 34 • This may explain the tendency for 
acute rejection to occur in the first few months following 
transplantation. In addition to the interaction between T-
cell receptor and the antigen-presenting cell together with 
MCH class II molecules, it is felt that the extracellular 
matrix also plays a role in T cell activation. Extracellular 
matrix may participate in T cell activation through binding 
to CD26 and VLA integrins. Moreover, the liver contains very 
little collagen and this may also explain why liver 
allograft rejection is less severe than other organ graft 
rejection35 • 
c) Chronic Rejection 
Many antigenic targets in the graft are similar since the 
bile ducts, endothelial cells and hepatocytes remain of 
donor origin and continue to express foreign MHC antigens. 
However donor Kupffer and dendri tic cells are replaced by 
those of the recipient18, 34, 
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The loss of bile ducts may be attributed to immunological 
damage directed against Class I or Class II MHC antigens or 
both. This is supported by the evidence of similarity 
between the bile duct lesion in liver transplantation to 
that seen in graft vs host disease20 • In end stage chronic 
rejection, the mononuclear portal inflammatory infiltrate is 
minimal and this may be because the target antigen in 
biliary epithelium is no longer present. 
Bile ductopaenia may also relate to ischaemia. The portal 
tracts and their bile ducts receive most of their blood 
supply from the hepatic artery. Any compromise of that 
supply could result in damage and lead to the disappearance 
of bile ducts18 • 
In the same way the obliterative arteriopathy is probably 
due to a combination of direct immunologic damage and 
ischaemic injury36, 
2.1.3 Patient data 
The majority of patients transplanted at Groote Schuur 
Hospital experienced acute rejection at 4-6 days post 
transplantation. This usually manifested as fever 
accompanied by leukocytosis, an increase in serum bilirubin, 
alkaline phosphatase and gammaglutamyl transferase levels 
followed by a rise in the transaminase levels. Some patients 
experienced myalgia and arthralgia. In those patients who 
had T-tubes, the bile was noted to decrease in amount and 
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become pale and watery at the time of rejection. The 
rejection episodes were mild in all cases except in 2 
patients (OLTx 2, 5). All responded to pulses of intravenous 
medrol, usually given as 500 mg or 250 mg boluses (depending 
on the severity) for 3 consecutive days and then 2 further 
pulses of medrol each following a day's break. No patients 
required OKT3, a monoclonal antibody for treatment of 
rejection. To date, none of our patients have experienced 
chronic rejection. The majority of our patients receive 
maintenance immunosuppression in the form of medrol, 
azathioprine and cyclosporine. 
2.2 THE ACUTE PHASE RESPONSE 
Tissue injury as a result of infection, physical and 
chemical trauma, malignancy and immunological disorders 
results in a complex series of local and systemic reactions 
collectively known as the acute phase response. Immediate 
local tissue responses include vasodilatation and the 
release of cellular contents such as lysosomal enzymes, 
prostaglandins and vasoactive amines. 
Secondary local responses include chemotaxis, with the 
influx of leukocytes and the production of leukotrienes and 
arachidonate metabolites together with the activation of 
monocytes/macrophages and the production of cytokines. The 
systemic reaction is characterised by fever, leukocytosis, 
increased vascular permeability, a negative nitrogen 
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balance, alterations in plasma metal and hormonal 
concentrations and an increase in the synthesis of acute 
phase proteins. Serum iron and zinc levels decrease and 
increased caeruloplasmin levels result in increased serum 
copper levels. There is an increased production of insulin, 
glucagon, growth hormone, TSH and ACTH37 , 38 , 39 • 
Most of the non-hepatic acute phase reactions are mediated 
by the cytokines Interleukin-! ( IL-1) and Tumour Necrosis 
Factor (TNF-alpha). Acute phase proteins are mainly hepatic 
in origin but some are also produced at extrahepatic sites. 
The principal mediators of the hepatic acute phase response 
are Interleukin 6 (IL-6), IL-1, TNF-alpha, Interferon (IFN) 
and the glucocorticosteroids. Al though many different cell 
types produce these hormones, the most important sources 
during a local inflammation for all these hormones except 
the glucocorticoids are activated macrophages, monocytes, 
fibroblasts and endothelial cells. Glucocorticoids act 
syngergistically with the cytokines to cause the induction 
of acute phase protein genes 37 • 
IL-6 is the major direct regulator of the hepatic acute 
phase response and can induce the full spectrum of acute 
phase proteins40 . IL-1 and TNF-alpha are important 
modulators of the hepatic acute phase response. They inhibit 
the induction of transcription of the genes for certain 
proteins known as the negative acute phase proteins 37 • Both 
IL-1 and TNF-alpha primarily released by activated 
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macrophages and monocytes can induce a potent release of IL-
6 from stromal cells41 and thus act indirectly on the liver. 
IFN exerts a regulatory action on the expression of several 
acute phase protein genes at extrahepatic sites. It induces 
the expression of complement C4 and factor Bin monocytes as 
well as acting as a macrophage activating factor promoting 
the release of IL-1 and IL-6 with consequent indirect 
induction of the acute phase proteins 37 • 
2.2.1 Acute Phase Proteins 
The acute phase proteins are structurally and functionally a 
diverse group but they all participate in the defence of the 
host against tissue damage and infection. They can be 
divided 
changes 
into 4 
during 
(concentration 
groups 
the 
according to 
acute 
increases 
phase 
2-fold) 
their concentration 
response. 
includes 
Group 
C3 
1 
and 
caeruloplasmin; Group 2 (concentration increases 2-10 fold) 
includes fibrinogen, haptoglobin, alpha-1-antitrypsin and 
alpha-1-antichymotrypsin; Group 3 ( concentration increases 
several hundred fold) includes C-reactive protein and serum 
amyloid A protein and Group 4 includes the negative acute 
phase proteins such as albumin and transferrin37 • 
C3 and CRP opsonise bacteria, parasites, foreign particles 
and immune complexes and facilitate their clearance by 
phagocytic cells. CRP participates in complement activation 
and may also play a role as clearance factor for chromatin 
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fragments by binding to chromatin released from damaged 
cells in inflammation, thus facilitating tissue repair. CRP 
may also act as a modulator of the immune response during 
inf lammation42 • Fibrinogen participates in clotting, wound 
healing and tissue regeneration. 
Many acute phase proteins are proteinase inhibitors 
including alpha-1-anti trypsin which inhibits leukocyte 
elastase, alpha-1-antichymotrypsin and alpha-macroglobulins 
which are both able to inhibit the activity of natural 
killer cells and antibody-dependent cell mediated 
cytotoxicity37 • Alpha-2 macroglobulins can suppress the 
chemotactic responses of monocytes and modulate the 
responses of lymphocytes to mi togenic and antigenic 
stimuli 43 • Alpha-2 macroglobulin also binds to cytokines 
including IL-1, TNF and IL-6 44 • Binding of these cytokines 
to the alpha-2 macroglobulin may affect the distribution, 
bio-availability, stability and clearance of cytokines44 • 
Binding of proteinase inhibitor complexes to their 
macrophage receptors suppresses superoxide anion production, 
proteinase secretion, Ia antigen expression, tumour cell 
killing and possibly antigen presentation by macrophages. 
Thus, the imunosuppressive functions of these proteinase 
inhibitor complexes play an important role in dampening down 
inflammatory and immune responses and in appropriately 
terminating an inflammatory episode37 • 
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Acute phase proteins play a critical role in the defence 
mechanisms promoting the clearance of invading particles and 
modulating the immune responses against them. They form part 
of the non-specific first line of defence and are 
particularly effective because of their rapid inducibility, 
providing protection immediately after an insult when the 
specific immune response is still ineffective. 
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CHAPTER THREE 
Physiology of BIie Secretion 
Bile is an aqueous solution of bile acids, cholesterol, 
phospholipids, bilirubin, bile pigments and inorganic 
electrolytes. Bile is secreted by hepatocytes into bile 
canaliculi, transported and modified by the intrahepatic and 
extrahepatic biliary system and delivered to the duodenum 
through the ampulla of Vater. After entry into the duodenum 
some bile constituents eg. bile pigments are excreted while 
others such as the bile acids are reabsorbed by the 
intestine, return to the liver and are re-excreted into bile 
via the enterohepatic circulation. 
The flow of bile is driven by the formation of osmotic 
gradients between the blood, the intercellular space and the 
hepatocyte on one hand and the lumen of the bile canaliculus 
on the other. These gradients are elaborated by the energy 
dependent transport of solutes from the hepatocyte into the 
canalicular lumen. Bile flows as these solutes are retained 
in the canalicular lumen and the gradients are dissipated by 
the passive movement of water and other solutes across the 
canalicular membrane and through tight junctions. The 
majority of solutes that make up these osmotic driving 
forces consist of organic anions, 
and their conjugates, which are 
particularly bile acids 
of sufficient size and 
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negative charge so as to be retained within the lumen by the 
tight junction barriers. Small amounts of fluid and solutes 
such as proteins, cholesterol and phospholipids are also 
transported into bile by the transcellular vesicular 
pathway. Small ions such as sodium diffuse through the tight 
junctions and maintain electroneutrality. The bile is then 
modified by secretory and absorptive processes along the 
bile duct epi thelia 45 , 46, 4 7. 
3.1. BILE SECRETION AND FLOW 
Three main processes have been postulated in the formulation 
of bile and subsequent bile flow. 
3.1.1. Bile acid dependent bile flow (BADF) 
Bile acids are the most concentrated organic solutes in bile 
and their excretion by hepatocytes is the major determinant 
of bile flow. There is a linear relationship between bile 
salt excretion and bile flow once bile acids exceed critical 
micellar concentrations 45 • Bile acids usually aggregate in 
micelles and their osmotic activity is thus reduced. Most of 
the osmotic activity of bile acids is provided by their 
accompanying counter-ions46 • Water and electrolytes are 
drawn into the canaliculi by osmosis and convection via 
paracellular routes through tight junctions that separate 
blood from bile at the canalicular leve148 . A small amount 
of water may enter the canaliculus via the transcellular 
route. BADF accounts for 30-60% of spontaneous basal bile 
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f low46 . 
3.1.2. Bile acid independent bile flow (BAIF) 
Significant bile flow may also be generated in the presence 
of low bile acid output. Impermeant organic anions can be 
concentrated in bile by carrier mechanisms driven by the 
membrane potential. This could provide an osmotic driving 
force for secretion. Glutathione an organic anion, 
synthesised in the liver, is secreted into bile in 
sufficient concentration to exert an osmotic driving force 
for paracellular and transcellular water movement49 . The 
inorganic transport mechanisms such as Na+/K+ -ATPase, 
Na+/H+ antiport, c1-/HC03--antiport and Na+/HC03--symport 
have been implicated but their exact role is uncertain45 ,4 6 . 
Bicarbonate excretion utilising the canalicular Cl - /HC03- -
antiport promotes BAIF4s,so. 
3.1.3. Reabsorption and secretion of fluid and electrolytes 
by the biliary ductules and ducts 
Finally bile secreted by the hepatocytes may be modified on 
its way through the ductules and ducts. The ductules are 
capable of absorbing water and NaCl and reabsorption is 
enhanced by somatostatin. Secretin increases duct secretion 
of water and this is accompanied by an increased secretion 
of bicarbonate46 . 
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3.2. BILE COMPOSITION 
3.2.1 Water and electrolytes 
TABLE 3.1. CONCENTRATIONS OF ELECTROLYTES IN HOMAN BILE51 
HEPATIC BILE GALLBLADDER BILE 
Range (Mean) Range (Mean) 
Na+ 132-158 mmol/1 (146) 156-264 (209) 
K+ 4.0-6.2 mmol/1 ( 4 . 8 ) 8.2-19.6 mmol/1 (12.8) 
ca2+ 1. 05-5. 6 mmol/1 ( 2 . 6 ) 3.1-17.2 mmol/1 (10.8) 
Mg2+ 0. 7-1. 5 mmol/1 not known 
c1- 83-117 mmol/1 (105) 66 mmol/1 
Other inorganic solutes include phosphorus and metallic ions 
( Fe, Cu, Zn, Mn ) . 
3.2.2 Organic solutes 
The main organic components of bile are conjugated bile 
acids, bilirubin, phospholipids, cholesterol and bile 
pigments. 
TABLE 3.2. CONCENTRATIONS OF MAIN ORGANIC SOLUTES IN HUMAN 
BILE. 
Bile acids 
Phospholipids 
Cholesterol 
Protein 
Bilirubin 
HEPATIC BILE 
Range (Mean) 
16-35 mmol/1 (25) 
1.3-5.6 mmol/1 (3.2) 
2.1-5.4 mmol/1 (3,6) 
1.4-2.7 mmol/1 (1.8) 
0.21-2.31 mmol/1 (1.11) 
GALLBLADDER BILE 
Range (Mean) 
14-118 mmol/1 (75.3) 
12.5-67.5 mmol/1 (33.5) 
4.9-21 mmol/1 (10.4) 
6.75 mmol/1 
0.62-10.8 mmol/1 (3.32) 
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Bile acids and their conjugates are the main organic 
solutes. The bile acids are conjugated with amino acids in 
the hepatocyte and exist mostly as taurine and glycine 
conjugates. Bile acids and salts form micelles above a 
critical micellar concentration46 . The major bile acids are 
conjugates of the primary (cholic and chenodeoxycholic) and 
secondary (deoxycholic, lithocholic and ursodeoxycholic) 
bile acids. Secondary bile salts are 
bacterial 7 alpha - dehydroxylation of 
acids4B. Bile acids are the major 
formed by colonic 
the primary bile 
determinant of 
phospholipid and cholesterol solubilisation in bile, 
incorporating them in mixed micelles. 
Biliary proteins include transport proteins such as albumin, 
transferrin, caeruloplasmin, haptoglobin, apolipoproteins 
and immunoglobulins such as secretory IgA, IgM and IgG. 
Hormones such as insulin, epidermal growth factor and 
cholecystokinin as well as enzymes including lysosomal 
hydrolases, amylase, and enzymes associated with the 
hepatocyte plasma membrane, mitochondria and endoplasmic 
reticulum are also found 46 • 51 • Circulating plasma proteins 
are transported into bile by transhepatocyte or paracellular 
pathways. The transhepatocyte pathway is associated with 
vesicular transport and exocytosis, the proteins may go 
directly to the bile canaliculus or they may interact with 
lysosomes52 • Biliary porphyrins exist mainly as copra-
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porphyrin, 80-90% being coproporphyrin-I. Protoporphyrin is 
also found in small amounts51 • 
3.3 MORPHOLOGY OF THE BILIARY SYSTEM RELATING TO BILE 
SECRETION 
Bile is formed by the hepatocytes and is secreted into 
canaliculi. Bile canaliculi are lµm in diameter, they branch 
and form a communicating network. Canaliculi are closed at 
one end situated near the central part of the hepatic lobule 
and at the other end situated near the portal space at the 
lobule periphery they drain into larger channels, the bile 
ductules which join to form bile ducts. The canaliculi have 
no walls of their own, they are bounded by the plasma 
membrane of the two adjoining hepatocytes. This area of the 
hepatocytes plasma membrane is known as the canalicular 
membrane and it has numerous microvilli which project into 
the lumen, thus providing a large surface area for 
secretion46 • 
The canaliculus is surrounded by a narrow area of organelle-
poor cytoplasm called the pericanalicular ectoplasm which 
contains actin microfilaments. These actin microfilaments 
insert into the area of the intercellular junction called 
the intermediate junction, form a network around the 
canaliculus and extend into the microvilli microfilaments. 
They may play a role in maintaining the shape of the 
canaliculi and microvilli 46 • The microfilaments undergo 
periodic contractions to facilitate propulsion of bile from 
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the central to the portal regions of the lobule53 • 
Microtubules which are involved in vesicular transport are 
more randomly distributed in the cytoplasm but are also 
found in the pericanalicular ectoplasm53 • 
The canaliculus is surrounded by two hepatocytes and tight 
junctions seal off the lumen from the intercellular space. 
The location of these junctions polarises the plasma 
membranes of the hepatocytes into an apical ( canalicular) 
and a basolateral domain. The basolateral domain is formed 
by the sinusoidal plasma membrane which faces the space of 
Disse and the lateral domain which contains the desmosomes, 
intermediate 
junctions46 • 54 • 
junctions, tight junctions and gap 
The desmosomes protect the membranes from deformation and 
damage due to distension. Intermediate junctions serve as an 
adhesive structure between the cells and provide attachment 
for the microfilaments. The permeability of the tight 
junction is important for the process of bile formation. 
Epithelial tight junctions vary in their permeability and 
those of the hepatocyte are of an intermediate type with 
numerous contact lines which are permeable to the flow of 
water and small solutes 45 •46 • They prevent the diffusion of 
organic solules out of bile. The tight junction is 
associated with a specific cytoplasmic protein called 
zo-1 54 • 
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The ductules and ducts are lined by true epithelial cells 
and have microvilli projecting into the lumen. The ducts in 
the portal tracts are supplied by branches of the hepatic 
artery. 
3.4. FACTORS DETERMINING THE BILE SECRETORY PROCESS 
3.4.1. The translobular gradient46 ,4 7 
There tends to be unidirectional blood flow through the 
hepatic lobule with blood flowing from the portal space 
through the sinusoids and then drained by a branch of the 
hepatic vein. Thus the periportal hepatocytes (Zone 1) are 
first exposed to afferent blood and receive blood with the 
highest solute concentration. The amount of solute removed 
by the hepatocytes as blood flows in the sinusoids towards 
the hepatic vein depends on the extraction efficiency for 
each solute. The periportal ( Zone 1) hepatocytes are the 
primary sites of bile acid dependent secretion. Hepatocytes 
in Zone III which are located at distal sites in the hepatic 
lobule adjacent to the terminal hepatic veins are relatively 
bile acid deficient because of the efficient first pass 
clearance in the periportal cells and secretion here is 
determined mainly by bile acid independent mechanisms. 
Blood flow through the sinusoids is not always 
unidirectional and pulsatile pressure changes within the 
sinusoids allow for mixing of solutes before hepatocyte 
uptake and thus reduce the steepness of the translobular 
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gradient. 
sinusoidal 
Bile flows in 
blood flow so 
the opposite 
that bile 
direction to the 
in the periportal 
canaliculi is more concentrated than that in canaliculi in 
the hepatic vein area. Bile flow is unidirectional and thus 
the concentrated bile in the periportal canaliculi does not 
come into contact with the Zone III hepatocytes which may 
contain lesser amounts of the same solute. Thus, back 
diffusion of solutes to the hepatocytes and sinusoidal blood 
is prevented. The trans lobular gradient favours the 
formation of bile with a high concentration of organic 
solutes. 
Portal Space To Hepatic Vein 
Figure 3 .1: The trans lobular gradient modified from 'What 
causes cholestasis' by J. Boyer in The American Association 
for the study of Liver Disease: New Frontiers in Liver 
Disease, October 1989. 
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3.4.2. Membrane transport systems and their structural 
polarity 
a) Na+/K+-ATPase 
This is an integral membrane protein which is responsible 
for maintaining a low intracellular Na+ and high K+ 
concentration by utilising metabolic energy derived from 
hydrolysis of ATP. It thus provides for inwardly directed 
Na+ gradients and outwardly directed K+ gradients. The 
ATPase membrane pump exchanges 3Na + for 2K+ and is thus 
electrogenic resulting in a negative intracellular electric 
potential. K+ exits from the cell through K+ channels 
thereby increasing the negative intracellular potential 
(usually - 35mV). The inwardly directed transmembrane sodium 
gradient provides the energy for driving a number of 
secondary active transport systems 50 • 
The Na+/K+-ATPase is situated on the sinusoidal membrane of 
hepatocytes where it provides the major driving force for 
secondary active solute transport in both directions across 
the sinusoidal plasma membrane as well as potential-driven 
anion excretion across the canalicular membrane50 • 
b) Other ion transport systems 
These include the Na+ /H+ antiport, HC03- /Cl - exchanger and 
the Na+ /HC03--symport. The Na+ /H+ exchangers and the 
Na+/HC03- symporters are present on the sinusoidal membranes 
whereas the HC03- /Cl - exchangers together with a chloride 
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conducive channel are found on the canalicular membrane. 
These ion transporters are important in maintaining cell 
homeostasis including intracellular pH, cell volume and ion 
composition. These ion transporters affect bile excretion 
since they are interrelated through effects on the 
transmembrane potential differences and ion gradients which 
in turn influence organic ion transport47 . 
In addition to the above primary and secondary active 
transport mechanisms, there are two tertiary active 
transport mechanisms, the sinusoidal OH-/S04- antiport and 
the canalicular (OH- or HC03-)/S04- antiport which are 
driven by ionic gradients established by secondary active 
transport mechanisms. The sinusoidal OH-/S04- antiport can 
move a variety of organic anion co-substrates in either 
direction across the sinusoidal membrane and the canalicular 
(OH- or HC03-) /S04- antiport can move similar anions into 
bile. 
c) Bile acid transporters 
Bile acids are the most concentrated organic solutes in bile 
and their excretion is the major determinant of bile flow. 
Only small amounts of biliary bile acids are derived from de 
novo synthesis from cholesterol. Thus most bile acids must 
be taken up across the sinusoidal membrane, transported 
transcellularly to the canalicular domain and then secreted 
into the canaliculi. Bile acid uptake into the hepatocyte 
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occurs against a concentration gradient and requires energy. 
Bile acid uptake may be sodium dependent and mediated by a 
sodium co-transport system45 • This transport system is thus 
a secondary active mechanism46 •50 as it uses the sodium 
gradient as its energy source which is maintained by the 
primary active transporter, Na+ /K+ -ATPase. A 48kD 
protein45 •50 has been identified in the sinusoidal membrane 
which acts as a Na+ coupled carrier for bile acids such as 
taurocholate, using the sodium gradient as the driving force 
to transport the anions against opposing chemical and 
electrical gradients. 
Bile acid uptake is also sodium independent and a sinusoidal 
transmembrane protein with molecular weight of 54kD has been 
identified. Unconjugated bile acids such as cholic acid may 
exchange with hydroxyl or sulphate ions as well as with 
other organic anions released by the liver suggesting that 
uptake of unconjugated bile acids may be mediated by a 
multispecific anion exchanger which might be identical to 
the 54kD bile acid transporting protein47 , 53 • 
The intracellular transport of bile acids from the 
sinusoidal to the canalicular pole of the hepatocyte depends 
mainly on the diffusion of free or protein-bound bile acids. 
Several cytoplasmic proteins including the Y protein 
(ligandin or glatathione transferase), Z protein (fatty acid 
binding protein) and Y' protein (alpha hydroxysteroid 
dehydrogenase) exist which bind bile acids and other organic 
anions 45 , 47 • Some bile acids are transported via microtubule 
dependent vesicular pathways into the canaliculus53 • 
Bile acids are excreted into bile against a concentration 
gradient. A lOOkD carrier protein has been identified in the 
canalicular membrane45 •50 • This carrier associated transport 
of bile acids into the canaliculus may be driven by the 
membrane potential in which the cytoplasm is negatively 
charged with respect to the canaliculus lumen, thus allowing 
the movement of negatively charged anions out of the cell 
and into the canaliculus. The formation of micelles, thus 
decreasing the concentration of free bile acids in the 
canaliculus also facilitates the movement of bile acids into 
the lumen. 
d) Other organic solutes 
Bile acid independent flow is thought to be generated by the 
biliary excretion of other osmotically active organic 
solutes. 
These organic solutes include anions (bilirubin, free fatty 
acids), cations and neutral compounds which are conjugated 
by the liver to increase their water solubility and 
facilitate excretion into bile45 • Uptake of the organic 
anions may involve the sinusoidal 54kD multispecific organic 
anion exchanger. 
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Glutathione is an organic anion which is synthesised by the 
hepatocyte and secreted into plasma and bile by carrier 
mediated mechanisms. Biliary excretion is active and is 
driven by the transmernbrane electrical potential. Biliary 
excretion of glutathione is one of the major determinants of 
bile acid independent flow4 9 • 
3.4.3 Intracellular organelles 
The transcellular vesicular pathway is responsible for the 
movement of large molecules such as IgA and transferrin. It 
involves endocytosis and exocytosis and is dependent on 
intact microtubules. Hepatic microsomes are involved in 
conjugating lipid soluble organic solutes into water soluble 
compounds for excretion into bile. Golgi vesicles may also 
be involved in excretory processes. Lysosomes may fuse with 
the canalicular membrane and release their contents into 
bile47 ,53. 
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Figure 3.2: Location of membrane transport systems in 
hepatocytes and bile ducts. Modified from 'Physiology of 
bile secretion and cholestasis' by M. Sellinger and J. 
Boyer. In: Progress in Liver Diseases. Vol. IX. Eds. H. 
Popper and F. Schaffner 
46 
CHAPTER FOUR 
Cholestasis 
Cholestasis occurs when the determinants of bile formation 
(as discussed in the previous chapter) are no longer able to 
maintain standing osmotic gradients between bile and the 
hepatocyte and the intercellular spaces. As the cholestatic 
liver injury progresses, these osmotic gradients dissipate 
and the driving force for osmotic filtration of bile is 
diminished. In many cholestatic disorders it is not certain 
whether these disturbances in the determinants of bile 
secretion are primary effects or secondary consequences of 
cholestatic injury. 
Cholestasis is associated with several 
disturbances including the following defects: 
functional 
1. Impaired transport of organic anions resulting in raised 
plasma and tissue bile salt levels associated with 
pruritus, retention of bilirubin causing jaundice. 
2. Defects in lipid excretion resulting in hypercholesterol-
aemia and associated xanthelasma, hyperphospholipidaemia 
and alterations in red cell membranes (target cells, 
burr cells). 
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3. Decreased intestinal bile salt concentrations resulting 
in steatorrhoea and consequent malabsorption of fat 
soluble vitamins (vitamins A, D, K, E). 
4. Increased synthesis or release of enzymes from liver 
plasma membranes manifested as raised serum alkaline 
phosphatase and gammaglutamyl transferase levels. 
Cholestasis is caused by a number of intrahepatic and 
extrahepatic disorders in which the disturbances in the 
determinants of bile secretion are often similar. 
4.1 PATHOPHYSIOLOGY OF CHOLESTASIS AS APPLICABLE TO 
ORTHOTOPIC LIVER TRANSPLANTATION 
4.1.1. Alterations in morphology 
a) Bile duct obstruction and anastomosis problems 
Morphological changes include progressive dilatation of the 
bile canaliculi and loss of canalicular membrane 
microvilli56 • In the hepatocytes, the number of Golgi 
vesicles decrease in the canalicular region and the smooth 
and rough endoplasmic reticulum is generally decreased. 
Intracellular vesicles, often containing bile pigment, 
lipids and secretory protein such as IgA increase in number 
near the secretory pole45 • 59 • The cytoskeleton is important 
in maintaining the structural polarity of the hepatocyte. 
During cholestasis, changes occur in the peri-canalicular 
cytoplasm which include an increase in number and disarray 
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of the actin microfilaments resulting in thickening of the 
peri-canalicular cytoplasm. These changes are associated 
with decreased canalicular contractility45 • Within the tight 
junction the number and density of contact lines decrease 
and are no longer arranged in parallel to the lumen of the 
canaliculus45 •57 • The cytoplasmic protein Z0-1 which is 
associated with the tight junction becomes discontinuous 
along the submembranous region of the junction58 • As a 
result of these structural changes junctional permeability 
is increased, resulting in a loss of the osmotic driving 
forces due to reflux of the bile acids and other osmotically 
active compounds into the intercellular space and then into 
the sinusoid. Loss of integrity of the tight junction also 
results in a loss of the structural and functional polarity 
of the hepatocyte leading to a redistribution of canalicular 
proteins ( alkaline phosphatase, bile acid 100 kD carrier 
protein) on the sinusoidal domain45 , 54. 
b) Intrahepatic cholestasis ( rejection, graft injury and 
hepatitis) 
Many similar morphological changes occur to those seen in 
extrahepatic bile duct obstruction.These changes include 
distortion of the cytoskeleton involving the microfilaments 
and impairment of the tight junctions with morphologic 
disruptions of the junctional strands and random cytoplasmic 
distribution of ZO-I proteins. Interleukin-6, a pro-
inflammatory cytokine has been shown to decrease expression 
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of intermediate junctions and desmosomes with consequent 
decrease in cell-cell contact60 • The resulting decrease in 
canalicular contractility and increased paracellular 
permeability to organic solutes is similar to that seen in 
extrahepatic cholestasis. 
4.1.2 Loss of the translobular gradient 
The translobular gradient is lost in cholestatic injury and 
the bile acids and other solutes which are normally 
predominantly cleared by the periportal cells accumulate in 
the circulation. Canalicular bile stasis tends to 
predominate in Zone III of the hepatic lobule47 . 
The maintenance of osmotic driving forces for bile formation 
is critical for sustaining this secretion. Thus factors 
which may increase the osmolarity of sinusoidal blood such 
as total parenteral nutrition may reduce the osmotic 
gradient between plasma and bile at the hepatocyte level and 
thus contribute to cholestasis 61 • 
4.1.3. Changes in membrane permeability 
Cellular function is dependent on the ability to maintain 
ion concentration gradients between intra and extracellular 
spaces. The hepatocyte membranes are relatively impermeable 
to Na+ and Ca2+ whilst readily permeable to Cl - and CO2. 
Steep concentration gradients between the cell and the 
extracellular space are maintained by plasma membrane ATP-
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dependent pumps (Na+ /K+ATPase and Ca 2+ ATPase) . Membrane 
injury may lead to an increase in Na+ and Ca2+ permeability 
leading to the dissipation of these ion gradients with 
resulting loss of Na+ coupled solute transport and increases 
in cytosolic calcium47 • The increase in cytosolic calcium 
may be due to failure of sequestration in the endoplasmic 
reticulum. Depletion of an essential regulatory calcium pool 
in the endoplasmic reticulum could impair a number of 
intracellular transport processes45 • 53 • Also, the increased 
cytosolic calcium levels may result in sustained tonic 
contraction of the canaliculi thus interfering with the bile 
flow47 • Monohydroxy bile acids such as lithocholate and its 
conjugates have been shown to increase the permeability of 
smooth endoplasmic reticulum to calcium ions, resulting in 
an increase in cytosolic calcium53 • Thus cholestasis 
associated with lithocholate may be due to impairment of 
intracellular transport processes associated with increased 
cytosolic calcium53 • 
Decreases in canalicular membrane permeability to water 
could also affect bile flow as that is one of the 
determinants of transcellular water flux 
independent of the osmotic driving forces 45 • 
which is 
However, whether the changes in membrane 
ions and water are the cause or the 
cholestasis is not known. 
permeability to 
consequence of 
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4.1.4. Changes in membrane fluidity 
Membrane fluidity relates to the specific composition of 
lipids and influences the activities of many membrane-bound 
enzymes including Na+/K+-ATPase. Both increases and 
decreases in membrane fluidity may be associated with 
inhibition of bile secretion suggesting that there is a 
narrow physiological range in membrane viscosity for optimal 
secretory function45,47. 
4.1.5. Alteration of membrane carriers, ion pumps and 
intracellular transport mechanisms for: 
a) Bile Acids: Inhibition of bile acid transport which 
results in a decrease in BADF may be due to a number of 
causes including: 
i) Alterations of the sinusoidal transport mechanisms: 
The sodium dependent uptake of bile acids may be 
impaired as a result of dissipation of the Na+/K+-ATPase 
dependent sodium gradient which may occur as a result of 
membrane injury. Membrane injury may also directly 
affect the sinusoidal transport carriers, i.e. 48 and 54 
kD carrier proteins45 • 4 7 . Moreover, competition for the 
Na+ dependent transport proteins as may occur between 
bile acids and amino acids may also result in decreased 
uptake45 . This competition may play a role in 
cholestasis seen in total parenteral nutrition. 
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ii) Alterations in transcellular transport: Rapid 
transport to the canalicular domain usually occurs as a 
result of diffusion of free or protein bound bile acids. 
Competitive binding by other substances to these 
cytosolic binding proteins may decrease bile acid 
excretory rate47 . Moreover, bile acids are also 
transported by microtubule dependent (ATPase Kinesin) 
vesicular pathways and are secreted by exocytosis53 . 
This pathway becomes increasingly important as the 
transcellular flux of bile acid increases and the 
intracellular organelles such as microsomes and Golgi 
vesicles may accumulate bile acids 53 . 
This may act as a protective mechanism during liver 
injury when bile acid excretion is impaired and 
intracellular bile acid concentrations reach detergent 
levels4 7 . This retention of bile acids results in a 
vicious cycle with increasing membrane damage and 
accelerated impairment in the bile secretory 
process45,47 ,62,63. 
iii) Alterations in canalicular excretion: Canalicular 
excretion is the rate limiting step in bile acid 
excretion. Injury to the 100 kD canalicular membrane 
carrier or depolarisation of the hepatocyte with 
resultant loss of the major driving force, i.e. 
transmembrane electrical potential difference, for 
excretion diminishes the ability of the hepatocyte to 
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excrete bile acids and generate bile flow. Also loss of 
functional hepatocyte polarity with relocalisation of 
the 100 kD canalicular protein to the sinusoidal domain 
as is seen in bile duct obstruction results in decreased 
bile acid excretion45,47, 
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b) Organic anions: Excretion of organic ions especially 
glutathione contribute to BAIF. Thus inhibition of uptake or 
excretion of these solutes may decrease bile flow45 •49 . 
c) Inorganic ions: Ion transport mechanisms including Na+/K+ 
antiport, Hco3-;c1- antiport and Na+/HC03- symport are 
thought to be impaired in cholestasis4 7 . This may be the 
result of membrane injury with consequent changes in 
membrane viscosity. Whether this is a contributory cause or 
a consequence of cholestasis is uncertain. Loss or 
inhibition of sinusoidal Na+ /K+ATPase activity results in 
alterations in ion gradients across the cell membrane which 
may inhibit bile acid uptake and other sodium dependent 
carrier mechanisms and thus inhibit bile secretion45 . 
4.1.6 Changes in bile duct function 
Bile secreted by hepatocytes is modified during its passage 
through the bile ductules and ducts 64 . Imbalances in duct 
secretion and absorption may play a role in cholestasis with 
a decrease in secretion resulting in inspissated bile45 . 
Increase in bile secretion is associated with bile ductular 
cell hyperplasia seen in extrahepatic cholestasis. 
4.2. Cholestasis post orthotopic liver transplantation 
Jaundice is frequently seen in the early post operative 
period, the pathogenesis is often uncertain and it may be 
multifactorial. Although rejection is always considered, a 
number of other aetiologies must be considered and excluded 
and if necessary a liver biopsy is performed before boosting 
immunosuppression. 
Common causes of cholestasis include: 
4.2.1. Biliary tract obstruction: 
Biliary tract complications are frequent as there is a high 
risk of breakdown of biliary anastomoses and/or biliary 
obstruction65 • 66 • 67 both of which are frequently associated 
with ascending infection. The frequency of biliary tract 
complications is thought to be related to the tenuous blood 
supply of the reconstructed common bile duct. The major 
blood supply to the bile duct is by small arterial branches 
that arise from the gastroduodenal artery (retroduodenal and 
retroportal arteries) and ascend along the bile duct68 • 
These arterioles are usually transected during donor 
hepatectomy and the allograft bile duct depends on arterial 
branches coming from the hilum of the liver65 • 
Early postoperative biliary tract complications are usually 
due to technical surgical problems or ischaemic injury 
resulting in obstruction at the anastomotic site, 
anastomotic breakdown or stricture formation. Multiple 
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intrahepatic strictures are usually associated with arterial 
thrombosis 65 • Patients with biliary obstruction may manifest 
with septicaemia with acute cholangi tis or with relapsing 
episodes of fever and fluctuating liver injury parameters. 
The diagnosis is usually made radiologically on ultrasound 
or cholangiogram. Histologically, there may be little to 
find if the diagnosis is made early. Otherwise typical 
findings include bile lakes and dilated, proliferative, 
tortuous ducts with periductal oedema. Perivenular 
cholestasis is seen but the presence of perivenular fibrosis 
usually suggests rejection. If cholangitis is present, there 
is a predominantly polymorph portal infiltrate present in 
contrast to the predominantly mononuclear portal infiltrate 
of rejection20 • Late biliary tract complications manifesting 
as multiple intrahepatic and extrahepatic strictures are 
usually associated with arterial compromise or are the 
consequence of cholangitis20 • Chronic rejection manifests as 
the vanishing bile duct syndrome and angiography may be 
necessary to confirm the associated obliterative 
arteriopathy. 
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Figure 4.1: Cholestasis with ductular proliferation 
4.2.2 Drug toxicity: 
Most patients receive a combination of steroids, 
cyclosporine and azathioprine as immunosuppression post 
transplantation. Immunosuppressive therapy including 
cyclosporine and azathioprine can be hepatotoxic. In the 
case of cyclosporine this tends to be dose related and is 
associated with a modest hyperbilirubinaemia and a mild 
elevation in transaminases which settle on decreasing the 
cyclosporine dosage. Documented histological changes include 
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cholestasis and 
hepatocytes20 • 
random acidophilic degeneration of 
Azathioprine has been associated with venosclerosis within 
the liver and glucocorticoids have been shown to induce 
hepatic steatosis20 • 
4.2.3 Hyperalimentation 
A complicated post-operative course following 
transplantation may necessitate prolonged total parenteral 
nutrition which may produce structural alterations. These 
changes include hepatocanalicular cholestasis, steatosis, 
cholangiolar proliferation with ductal cholestasis, 
steatosis, pigment deposition and sinusoidal fibrosis 20 • 
4.2.4 Infections 
a) Bacterial infections such as acute cholangitis and 
ascending infection. Ductular cholestasis, where dilated 
ductules contain inspissated concretions of bile, is often 
associated with systemic infections or septicaemia18 • 
b) Viral infections: 
Cytomegalovirus hepatitis is common and is usually due to 
reactivation of a latent virus. It occurs most frequently 4 
to 5 weeks after initiation of the immunosuppressive regime. 
Patients present with pyrexia, myalgia, arthralgia and 
mucosa! ulceration and have prolonged abnormal liver 
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function tests . It is often difficult to distinguish this 
rejection. Serology usually reveals clinically from 
reactivation of a latent infection and cultures including 
throat gargles and urine cultures may be positive. Liver 
biopsy confirms the nuclear or cytoplasmic cytomegalovirus 
inclusion bodies together with microgranulornas20 • 
Figure 4.2: CMV Hepatitis 
Hepatitis B: Patients with chronic active hepatitis B prior 
to transplantation usually have a recurrence of hepatitis B 
in the graft 3 • They present with malaise, jaundice and an 
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increase in transaminase levels coincident with the 
reappearance of HBeAg in the serum and HBcAg in tissue. 
Histologically there is a preferential lobular insult with 
little or no damage to structures targeted by rejection, 
i.e. bile ducts and venous endothelium20 . 
Non A, Non B hepatitis and Hepatitis C tend to recur less 
frequently post liver transplantation than hepatitis B3 • 
4.2.5. Vascular thrombosis 
Portal vein and hepatic artery thrombosis may occur in the 
first four months following transplantation and usually 
within the first two weeks. Thrombosis is often associated 
with sepsis complicated by a coagulopathy requiring multiple 
transfusions. The clinical picture varies from an almost 
asymptomatic patient to that of a rapidly progressive 
deterioration in liver function necessitating retransplant-
ation. 
4.2.6. Functional cholestasis 
Pure parenchymal cholestasis without associated rejection or 
bile duct inflammation may be seen in the early 
postoperative period, particularly in patients in a poor 
condition pre-operatively with associated coagulopathy 
postoperatively requiring multiple transfusions 69 . 
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4.2.7 Preservation injury 
This may be associated with a cholestatic syndrome which 
resolves spontaneously. Histologically there is ballooning 
degeneration of hepatocytes together with centrilobular 
cholestasis 70 • 
4.3 TRANSPLANTATION EXPERIENCE AT GROOTE SCHUUR HOSPITAL 
As can be seen, cholestasis may be a common problem post 
transplantation and there may be numerous causes. It is 
important to make the correct diagnosis in order to 
institute appropriate treatment. It is often difficult to 
clinically 
infections 
distinguish rejection 
especially viral without 
from ischaemia 
performing a 
or 
liver 
biopsy. If a liver biopsy is required, histological 
interpretation is much easier if it is performed prior to 
boosting anti-rejection therapy. 
Five of our transplant patients have experienced prolonged 
cholestasis following orthotopic liver transplantation. The 
management of cholestasis 
aetiological diagnosis. This 
included 
involved 
establishing the 
taking regular 
specimens of T-tube bile for culture to exclude biliary 
sepsis; T-tube cholangiograms and ultrasound of the liver 
were performed to exclude biliary obstruction. If hepatic 
artery thrombosis was suspected, angiography was performed. 
Liver biopsies were performed as indicated. Cyclosporine 
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levels were regularly monitored to maintain 
therapeutic levels. 
optimum 
In two patients (OLTx 2 
aetiological factor as 
& 5), rejection was the only 
infection and biliary tract 
obstruction were excluded and there was no evidence for any 
ischaemic or preservation injury. One patient (OLTx 7) 
experienced prolonged cholestasis associated with delayed 
graft function as a result of a severe preservation injury. 
One patient (OLTx 8) had cholestasis associated with a 
prolonged coagulopathy requiring multiple transfusions and 
infection in the form of bilateral lower lobe pneumonia and 
a mild CMV hepatitis. Another patient (OLTx 11) had 
prolonged cholestasis associated with a severe ischaemic 
injury with the subsequent development of an obstruction at 
the biliary tract anastomosis 
the biliary tract with 
requiring reconstruction of 
the formation of a 
choledochojejunostomy. However, despite the refashioning of 
the biliary tract anastomosis, this patient remained 
jaundiced and T-tube cholangiogram revealed the development 
of intrahepatic biliary strictures and a biliary leak at the 
site of the anastomosis (biloma) as a result of the previous 
ischaemic injury. This required insertion of two 
percutaneous biliary drainage catheters, one placed across a 
significant stricture at the origin of the left hepatic duct 
and the other draining the biloma. These catheters 
established good biliary drainage and the biloma decreased 
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in size. His post-operative course was further complicated 
by the development of a significant CMV hepatitis. At 
present, he still has an external biliary drainage catheter 
and may subsequently require internal stenting. If the 
intrahepatic strictures progress, in association 
chronic hepatic ischaemia, retransplantation may 
necessary. 
with 
be 
All of the above patients experienced acute rejection but 
this was only severe in two patients (OLTx 2 & 5). These 
patients all received total parenteral nutrition usually 
only for a period of 3 days, but two cases (OLTx 7 & 11) 
received TPN for 7-10 days. 
The medical treatment consisted of treating rejection with 
pulses of medrol and maintaining cyclosporin blood levels. 
Infections were treated appropriately. Bile salts in the 
form of ursodeoxycholic acid are administered not only to 
improve absorption of lipid, fat soluble vitamins and 
cyclosporin, but also as a protective mechanism. 
Ursodeoxycholic acid is hydrophilic and thus less toxic than 
other bile acids in cholestasis and it also promotes bile 
secretion in addition to blocking biological effects of 
endotoxin. 
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CHAPTER FIVE 
Cytokines 
Cytokines are a group of glycosylated or non-glycosylated 
polypeptides which are produced by activated lymphocytes and 
monocytes/macrophages as well as by a number of other cells, 
e.g. endothelial cells. Their biological activity is not 
dependent on their glycosylation 71 • They act as 'messenger 
molecules' , by which cells communicate and modulate each 
other's functions. Cytokines can be active in a local 
environment in an autocrine or paracrine manner or may 
disseminate widely and act as classical hormones 72 • 
The effects of cytokines may be due to: 
i) A single cytokine working alone; 
ii) Quantitative effects increased or decreased according to 
the status of second signals; 
iii) Synergistic where one cytokine alone has no effect in 
the absence of a second one73 • Synergistic effects of 
cytokines may be as a result of 1) cascade activation in 
which a T cell is activated to divide by a signal which 
includes IL-2 and the activated cell releases more IL-2 
which acts on both the original cell and on other 
responsive cells; 2) Dual activation in which some cells 
such as macrophages require triggers from two different 
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cytokines together, before developing their full range 
of functions; 3) Receptor induction73 • 
Unrelated cell types can produce the same cytokine and a 
single cytokine can affect numerous other cell types. Most 
cytokines are not secreted constitutively but stimulation or 
activation of the cell is necessary to induce cytokine gene 
transcription and production. The activity of each cytokine 
is determined by the presence of specific high-affinity 
receptors on responding cells. There tends to be no cross-
reactivity at receptor level and receptor expression is 
regulated. Post receptor signal transduction is poorly 
delineated as yet, but activation of various protein kinases 
with subsequent protein phosphorylation appears to play a 
role74 . 
Cytokines participate in a number of cellular responses 
including the regulation of the immune system where they are 
involved in 5 major areas, namely T Cell activation, B Cell 
activation, haematopoeisis, toxicity and inflammation. 
In this chapter, the roles of Tumour necrosis factor-alpha 
(TNF-alpha), Interleukin I (IL-1) and Interleukin 6 (IL-6) 
will be discussed in terms of the immune response and the 
hepatic acute phase reaction. 
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5.1. INTERLEUKIN I (IL-1) 
There are two structurally related IL-I namely alpha and 
beta, both of which are encoded by genes on chromosome 2. 
IL-1 alpha and IL-1 beta have 26% amino acid homology and 
45% homology at nucleic acid level. Despite this lack of 
homology they both bind to the same receptor and have 
similar biologic activities 75 • 
Interleukin I is produced by a wide variety of cells 
including T and B lymphocytes, natural killer (NK) cells, 
macrophages, skin keratinocytes, brain astrocytes, 
microglia, mesangial cells and the endothelium72 • IL-1 beta 
has a molecular weight of 17kD and is the predominant form 
synthesised by macrophages. The production of IL-1 is 
induced by antigens, toxins, injury and inflammatory 
processes. Monocytes and macrophages produce IL-1 in 
response to bacterial products such as endotoxin, immune 
complexes, complement cleavage product C5a and many 
cytokines including TNF-alpha, macrophage colony-stimulating 
factor (M-CSF) and gamma-interferon ( IFN) . The principal 
target cells for IL-1 are T and B lymphocytes, macrophages, 
endothelium and tissue cells73 • 
IL-1 receptors are found on many cells including leukocytes, 
haemopoietic cells, smooth muscle cells, endothelium, 
fibroblasts, chrondrocytes, hepatocytes, epidermal cells and 
pituitary cells 76 • The IL-1 receptor is a single chain 
molecule with molecular weight of 80 kD. The exact mode of 
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post receptor signal transduction is not certain. It has 
been suggested that IL-1 transiently increases cAMP and that 
the activation of adenyl cyclase involves a GTP-binding 
protein77 • 78 . Other reports suggest that IL-1 binding 
induces the transient production of diacylglycerol generated 
from phosphatidyl turnover ultimately leading to activation 
of a protein kinase79 • During IL-1 signal transduction, the 
binding of IL-1 to its receptor not only results in 
phosphoregulation of the receptor, but also leads to the 
translocation of the ligand-receptor complex into the 
nucleus82 • IL-1 may also induce increases in prostaglandin 
E2 levels in target cells 74 •80 • Native IL-1 inhibitors exist 
and distinct factors with molecular weights of 8kD, 20-25kD 
and 95kD have been identified83 • These inhibitors prevent 
the deleterious effects of unbalanced IL-1 secretion. 
Autoantibodies to IL-1 also exist88 and may serve as a 
carrier for IL-1, thereby retarding clearance and protecting 
the cytokine from proteolytic degradation. These 
autoantibodies may also have a protective function by 
controlling potentially dangerous stimulation of circulating 
lymphocytes. 
5.1.1 Involvement in the immune system 
IL-1 acts like an endogenous adjuvant serving as a cofactor 
during lymphocyte activation, primarily by inducing the 
synthesis of other lymphokines and the activation of resting 
T lymphocytes. Resting T helper lymphocytes recognise 
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antigens once they are presented on the surface of a 
macrophage together with MHC Class II molecules. The 
processed antigen is presented to the resting T cell 
together with IL-1. The resting T helper cell is activated 
and secretes a number of cytokines including IL-2, 3, 4 and 
6 and gamma-IFN72 • IL-1 increases T cell production of 
IL-2 74, 71 and increases IL-2 receptor expression72 • IL-1 
enhances the initial T-helper cell activation in the 
presence of IL-2. 
B cells are activated in a multistep cascade that begins 
with a small resting B cell and ends with a plasma cell 
committed to producing one type of antibody. The activation 
involves specific activation of the virgin or memory B cell, 
proliferation and clonal expansion and differentiation into 
antibody producing cells. Initial activation involves 
binding of the antigen to the immunoglobulin on the surface 
of the small resting B cell which is then converted to a 
large proliferating cell and further activation then 
requires B cell growth or stimulating factors. IL-2 plays a 
central role in regulating B cell activation, proliferation 
and differentiation into immunoglobulin producing plasma 
cells 74 • A number of cytokines including IL-6 can amplify 
antibody production but only in the presence of IL-2. 
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IL-1 which plays a role in B-cell activation, stimulates the 
synthesis of IL-6 and enhances its action41 . IL-1 synergises 
with IL-6 to enhance immunoglobulin production in the 
presence of glucocorticoids81 • 
5.1.2. Acute phase response 
IL-1 together with TNF-alpha and IL-6 are involved in the 
acute phase response of the liver37 •86 • IL-1 inhibits the 
synthesis of the negative acute phase proteins such as 
albumin and transferrin and also inhibits the synthesis of 
the positive acute phase protein, fibrinogen84 •85 • It 
inhibits the induction of transcription of these genes86 • It 
also stimulates the hepatic synthesis of complement factor B 
and C3. IL-1 can indirectly affect the hepatic acute phase 
response by stimulating the synthesis of IL-6 in fibroblasts 
and other stromal cells 37 • IL-1 also acts as a pyrogen and 
can stimulate enzyme 
chrondrocytes 73 • 86 • 
synthesis in osteoclasts 
5.2 TUMOUR NECROSIS FACTOR ALPHA (TNF-ALPHA) 
and 
TNF-alpha exists as a secreted form (17 kD) and as a cell 
associated transmembrane form ( 26kD). The 26 kD 
transmembrane molecule is a precursor of the 17 kD secretory 
component but may also have inherent bioactivity as a 
paracrine mediator. The gene for TNF-alpha is situated on 
the short arm of chromosome 687 • 
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TNF-alpha is synthesised by activated T cells, macrophages, 
monocytes, natural killer cells and the Kupffer cells of the 
liver. A wide variety of infections or inflammatory stimuli 
are capable of triggering TNF-alpha biosynthesis including 
bacterial endotoxin, enterotoxin, viruses, CSa and fungal or 
parasite antigens. IL-1 and Interferon-gamma enhance TNF-
alpha biosynthesis87 . 
The TNF-alpha receptors are found on activated T and B 
cells, natural killer cells, macrophages, neutrophils, 
haematopoietic stem cells, endothelial cells, fibroblasts, 
hepatocytes, adipocytes and osteoclasts. TNF-alpha receptors 
can be upregulated on some cells by gamma-1FN74 . The TNF-
alpha receptor has a molecular weight of 300kD and consists 
of dissimilar subunits. The binding subunit of the receptor 
is thought to have a molecular weight of 7 5kD11 . The TNF-
alpha receptors are a high affinity type and the receptor-
ligand complex is internalised but the mode of post receptor 
signal transduction is not clear11 • 87 . However, TNF-alpha 
has been shown to induce phosphorylation of a 28kD stress 
protein and induce the synthesis and myristoylation of a 
specific protein kinase C substrate85 • 
TNF inhibitors exist which appear to be a soluble form of 
membrane associated TNF receptor89 , 90 • Autoantibodies to TNF 
also exist88 • 
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TNF-alpha acts in synergy with IL-1 with which it shares 
many systemic properties and with IFN-gamma. Depending on 
the concentration of TNF-alpha , duration of exposure and 
presence of other mediators ( IL-1 and gamma-IFN) in the 
cellular environment, the net biological effects may either 
benefit or injure the host. Acute systemic release results 
in septic shock and tissue injury; persistent TNF-release 
provokes cachexia and if lesser amounts are released into 
tissues, the beneficial effects may predominate and mediate 
enhanced host defence against pathogens and coordinate 
tissue remodelling73, 87 . 
5.2.1 Involvement in the immune system 
TNF-alpha is a primary mediator in the pathogenesis of 
infection, injury and inflammation and in the beneficial 
processes of host defence and tissue homeostasis. 
TNF-alpha induced tissue injury is partly mediated by 
enhanced endothelial procoagulant activity which promotes 
fibrin deposition and diffuse intravascular 
coagulation73 •87 . TNF also promotes adherence of neutrophils 
to the endothelium as a result of increased expression of 
endothelium leukocyte adhesion molecules (ELAMS) 11 , 87. 
Leucostasis occurs as a result of increased expression of 
intercellular leukocyte adhesion molecules (ICAMS) 87 . The 
adherent neutrophils are stimulated by TNF-alpha to 
degranulate and form reactive oxygen intermediates such as 
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superoxide anions and hydrogen peroxide. TNF-alpha is 
chemotactic for macrophages and neutrophils and it increases 
their phagocytic and cytotoxic activity73 •87 • TNF-alpha 
activates natural killer and killer cells. 
Many of the harmful effects of TNF-alpha are caused by the 
induction of mediators including peptide regulating factors 
such as IL-1, IL-6, granulocyte macrophage-colony 
stimulating factor (GM-CSF), Platelet-Derived Growth Factor 
(PDGF), Transforming Growth Factor beta (TGF-beta) and 
eicosanoids such as prostaglandins, 
platelet-activating factor87 . 
leukotrienes and 
Septic shock appears to be the result of immunological over-
responsiveness to an invasive stimulus with the lethal 
toxicity of TNF-alpha synergistically influenced by IL-1, 
INF-gamma and LPS87 • 
TNF-alpha acts as a pyrogen both as a result of a direct 
effect on the hypothalamus and by inducing IL-1 synthesis87 • 
It can also regulate the biosynthesis of several metabolic 
enzymes. The catabolic rate of adipocytes and skeletal 
muscle increases with resulting increased 
glycogenolysis. Glucagon mediated amino 
lipolysis and 
acid uptake 
increases and there is decreased lipoprotein lipase activity 
with consequent hypertriglyceridaemia. The derangements of 
lipid and protein metabolism induced by TNF-alpha resemble 
the metabolic alterations associated with injury, infection 
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or chronic illness which include increased whole-body energy 
expenditure, lipolysis and protein turnover11 •87 • 
TNF-alpha is also involved in tissue remodelling. TGF-beta 
which is a TNF-alpha inducible cytokine,may suppress TNF-
alpha induced inflammation by suppressing the hydrogen 
peroxide releasing capacity of neutrophils and decreasing 
leucocyte adherence to endothelium87 • 91 • TNF-alpha may act 
as a growth factor, stimulating fibroblasts and mesenchymal 
proliferation directly. Together with TGF-beta it can 
promote angiogenesis87 • As a destructive mediator TNF-alpha 
induces the biosynthesis of collagenases and proteases. 
Phagocytosis of senescent glycosylated tissue proteins 
triggers macrophages to secrete TNF-alpha and IL-1 which 
then amplify the degradative and reparative mechanisms of 
normal tissue remodelling87 • 
5.2.2 Acute phase response 
TNF-alpha is less potent than IL-1 but it also indirectly 
affects the hepatic acute phase response by stimulating IL-6 
synthesis in fibroblasts and other stromal cells 37 , TNF-
alpha also causes significant downregulation of negative 
acute phase proteins including albumin, transferrin, and to 
a lesser extent, fibronectin84 • It may also stimulate 
hepatic synthesis of complement factor Band c3 37 , 85 , 
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5.3 INTERLEUKIN 6 
IL-6 is a glycopeptide derived from a precursor protein of 
212 amino acids by removal of a N-terminal hydrophobic 
leader peptide. It has two potential N-glycosylation sites 
and has a molecular mass ranging from 21-28kD depending on 
the cellular source92 . The gene for IL-6 has been localised 
to chromosome 7 (7p21) 92 . IL-6 is produced by a variety of 
cells including fibroblasts, keratinocytes, endothelial 
cells, monocytes/macrophages, bone marrow stromal cells, T 
and B cells and the folliculostellate cells of the anterior 
pituitary92 . A number of cell lines including T cell lines 
(HTLV-I transformed), monocyte lines (U937), T24 bladder 
carcinoma line as well as Tumour cells such as myeloma and 
cardiac myxoma cells also produce IL-6 10 • Hepatocytes do not 
produce IL-6 although certain hepatoma cell lines do produce 
IL-6 37 . 
In the steady state, IL-6 is not usually constitutively 
produced by normal cells, but its expression is readily 
induced in response to injury such as viral or bacterial 
infections, and physical or chemical trauma92 . A number of 
cytokines including IL-1 and TNF-alpha either alone or in 
combination with IFN-alpha, platelet derived growth factor, 
IL-3 and GM-CSF also induce IL-6 production92,93, 94,95. 
Compounds which activate protein kinase C have been shown to 
stimulate IL-6 gene expression in fibroblasts 92 , suggesting 
that the protein-kinase C dependent signal transduction 
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pathway may trigger IL-6 gene expression. The production of 
IL-6 in fibroblasts in response to IL-1 is cAMP dependent 
and protein kinase 
negatively regulate 
C 
IL-6 
independent 92 • Glucocorticoids 
gene expression10 • 37 •85 • The 
existence of multiple mechanisms of IL-6 gene regulation is 
consistent with the presence of several transcriptional 
enhancer elements ( glucocorticoid responsive element, AP-1 
binding element, cyclic AMP responsive element, C-fos serum 
responsive element and NF-kB binding element) in the 5' 
flanking region of the IL-6 gene92, 96 ,97,98. 
IL-6 receptors may be of a high or low affinity 
variety92 • 99 • lOO. The IL-6 receptor is a glycoprotein with a 
molecular weight of 80 kD consisting of 449 amino acids. The 
extracellular portion of the molecule contains 340 amino 
acids with a 90-residue N-terminal loop characteristic of 
the Ig superfamily. There is a transmembrane domain which 
consists of 28 residues and is followed by an 
intracytoplasmic segment of 82 amino acids. The intra-
cellular segment of the IL-6 receptor lacks a tyrosine-
kinase domain101 • Moreover, it is thought that the 
intracellular domain of the IL-6 receptor plays no role in 
the transduction of the IL-6 signal as a soluble form of the 
receptor lacking the transmembrane and intracellular domains 
is still responsive to IL-6. After binding of IL-6, the 80 
kD receptor associates with a 130 kD glycoprotein and it is 
thought that the IL-6 signal may be transduced by the 130 kD 
glycoprotein rather than by the IL-6 receptor itself. The 
130 kD glycoprotein may also stabilise the complex between 
IL-6 and the 80 kD receptor and thus increases the binding 
affini ty102 . 
IL-6 circulates in serum as a complex with alpha 2-
macroglobulin105. The liver is the major target organ104,l06 
of IL-6 where it is taken up by both hepatocytes and Kupffer 
cells, degraded and excreted into bile104 . IL-6 is also 
cleared by the kidneys106 . It has also been shown that after 
binding, IL-6 is released from the hepatocyte membrane and 
transported to skin where it is degraded107 . 
However, IL-6 is a pleiotropic cytokine and thus the IL-6 
receptor is found on many cell lines including those of 
epithelial, fibroblastic, haematopoietic and neural 
origin10 •92 •98 . Dexamethasone increases the expression of the 
IL-6 receptor103 . 
5.3.1 Involvement in the immune system 
IL-6 plays a major role in the terminal differentiation of B 
lymphocytes into immunoglobulin producing plasma cells 
particularly in the presence of IL-2. IL-6 receptors are 
expressed on activated but not on resting B cells indicating 
that IL-6 acts only on the final maturation stage of 
activated B cells108 •109 . IL-6 is not involved in the growth 
of activated B-cells 74 . Synergy exists between IL-1 and IL-6 
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in presence of glucocorticoids to enhance immunoglobulin 
production81 • 
IL-6 acts as an essential competence factor which synergises 
with IL-1 to control the initial steps of T cell activation. 
This synergy relates partly to the fact that IL-6 acts 
predominantly by enhancing IL-2 responsiveness as a result 
of IL-2 receptor induction whereas IL-1 increases IL-2 
production 92 • IL-6 also stimulates proliferation of 
activated lymphocytes 92 and TNF-alpha may act 
synergistically with IL-6 in inducing T cell growth110 • IL-6 
together with IL-1 can function as a killer helper factor in 
the induction and proliferation of cytotoxic T 
lymphocytes10 • 92 • 
IL-6 also stimulates the proliferation of mature CD4+ cos-
and CD4- coa+ thymocytes111 and the differentiation of 
cytolytic T cells from thymic precursors112 •113 . IL-6 induces 
serine esterases which are required for the expression of 
cytotoxic function112 . IL-1 induces IL-6 production in 
thymocytes and increases their sensitivity to IL-6 114 • 
IL-6 receptors are expressed on resting T lymphocytes and 
the expression of IL-6 receptor is downregulated upon T-cell 
activation108 • IL-6 is important in the initial stages of T 
cell activation and its main role is to move T cells from Go 
to an early G1 phase where they can become responsive to IL-
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2 and further progression into the cycle is then controlled 
by IL-1 which is required for IL-2 induction115 • 
5.3.2 Acute phase response 
IL-6 is the major direct regulator of the hepatic acute 
phase response84 •116 •117 •118 •119 • Both IL-1 and TNF-alpha 
released primarily by activated monocytes-macrophages induce 
a potent release of IL-6 from stromal cells37 and thus 
indirectly af feet the hepatic acute phase response92 • It 
induces the full spectrum of acute phase proteins including 
serum amyloid A, C-reactive protein, haptoglobin, alpha 1-
antichymotrypsin, alpha 1-antitrypsin, fibrinogen, alpha 1-
acid glycoprotein, caeruloplasmin and complement factor B; 
whereas the synthesis of the negative acute phase proteins 
including albumin, transferrin, fibronectin and C3 is 
considerably decreased116 • 117 • 118 • 119 • IL-6 exerts its control 
on acute phase proteins partly at the transcriptional 
level92 • It induces the interaction of specific nuclear 
factors (i.e. DNA binding proteins) with IL-6 responsive 
promoter elements of several acute phase protein genes85 • 
IL-6 also contributes to the host's defences by inducing 
fever and stimulating the release of ACTH92 • 
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was felt that measurement of biliary cytokines might be more 
specific for liver rejection than serum levels. 
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CHAPTER SIX 
Patients, Methods and Results 
6.1 PATIENTS 
Eleven patients have undergone orthotopic liver 
transplantation at Groote Schuur Hospital since October 1988 
(see Chapter 1). All experienced episodes of acute rejection 
and in two patients this was severe (OLTx 2 and 5). 
Diagnosing the rejection clinically is not always 
straightforward as there may be other contributing factors to 
liver dysfunction such as infection, drug toxicity, previous 
ischaemic or preservation injuries. Diagnosis must often be 
confirmed histologically. Liver biopsy may however be 
contraindicated because of coagulation abnormalities, ascites 
or biliary dilatation. Analysis of the biochemistry and 
cytokine concentrations of bile obtained from the T-tubes of 
transplant 
diagnostic 
patients 
aid. Of 
may 
the 
provide an 
11 patients 
early non-invasive 
who have undergone 
orthotopic liver transplantation, nine had external biliary 
drainage, i.e. the common bile ducts of donor and recipient 
were anastomosed end-to-end over a T-tube. The T-tube is 
usually clamped at 14 days but remains in situ for 3 months 
before it is removed under antibiotic cover. This allows easy 
access to the biliary tract should a cholangiogram be 
necessary to exclude obstruction. The bile usually flows via 
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the T-tube into the external biliary drainage bag as well as 
into the duodenum. Occasionally, however, there may be 
preferential drainage into the duodenum. In these cases there 
may be little or no external drainage of bile. 
Although 9 of our patients had T-tubes, we were only able to 
collect bile from 7 patients (OLTx 2, 3, 4, 6, 7, 8, 11). 
Serial bile samples were obtained from 4 patients (OLTx 6, 7, 
8, 11). Bile samples were obtained at time of clinical 
rejection, viral infection or cholestasis in the remainder of 
the patients. Bile was also obtained from organ donors and 
used to set baseline values. 
6.2 METHODS 
6.2.1 Collection of bile samples 
Bile samples were collected daily where possible from the 
external biliary drainage tubing and reservoir of the 
patients and stored in aliquots of 2 ml at -70°C. The donor 
bile was obtained from the gallbladder at the time of 
harvesting and prior to flushing with Wisconsin preservation 
solution. 
6.2.2 Evaluation of hepatic function 
Liver function tests including serum biochemistry (bilirubin, 
transaminases, gammaglutamyl transferase and alkaline 
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phosphatase levels) and coagulation profiles (platelets, INR, 
partial thromboplastin time, fibrinogen levels) were 
performed daily. If the clinical findings together with 
abnormal liver function tests suggested either allograft 
rejection or cholestasis due to another cause, then further 
investigations such as abdominal ultrasound, T-tube 
cholangiogram and liver biopsy were performed. 
6.2.3 Biliary biochemical parameters, cytokines and porphyrin 
measurements 
a) Biochemical parameters 
Measurement of the biliary biochemistry was performed by the 
Department of Chemical Pathology, Groote Schuur Hos pi ta!. 
Once the appropriate bile dilutions were made, all 
measurements were automated using the Boehringer Mannheim 
Hitachi System 704 machine and the Beckman ASTRA™ machine. 
The principles of measurement are presented below. 
The biochemical parameters measured included: 
(i) Total bilirubin: This was measured on the HITACHI 704 
and the method used is the modified Jandrassik and Grof 
method. Bile is reacted with diazotized sulphanilic acid 
in a solution of acetate buffered caffeine benzoate which 
accelerates the coupling of bilirubin to the diazotized 
sulphanilic acid. 
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(ii) Gammaglutamyl transferase (GGT): This was measured 
on the HITACHI 704 and depends on the ability of GGT to 
catalyse the cleavage and transfer of gammaglutamyl 
residues from peptides or other compounds to an acceptor. 
i.e. L-y-glutamyl-3-carboxy-4-nitroanilide + 
glycylglycine GGT) L-y-glutamyl-glycylglycine + 5-amino-
2-nitrobenzoate. 
(iii) Alkaline phosphatase (ALP): This was also measured 
on the HITACHI 704. This measures the ability of alkaline 
phosphatase to cleave phosphate groups from a wide 
variety of substrates. 
i.e. p-Nitrophenylphosphate + H2o ALP) Phosphate+ p-
nitrophenol. 
(iv) Calcium and magnesium: These were both measured on 
the HITACHI 704. The measurement of calcium depends on 
the ability of ca2+ to form a violet complex with o-
cresolphthalein complexone in an alkaline medium. 
Magnesium ions form a purple-red complex with xylidyl 
blue in an alkaline solution. The magnesium concentration 
is measured bichromatically in terms of decrease in 
absorbance of xylidyl blue at 660/700 nm. Interference by 
calcium is prevented by EGTA present in the buffer. 
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(v) Sodium, potassium and chloride: These were all 
measured on the ASTRA™. The sodium-potassium chemistry 
module uses ion-selective electrodes to determine the 
presence of these ions in a solution. When the mixture of 
sample in buffer comes into contact with the ion-
selective electrode an ion exchange (sodium) or ion 
complexing (potassium) occurs, resulting in a change in 
voltage potential at the electrode. This potential 
follows the Nernst equation allowing the calculation of 
sodium or potassium concentration in solution. 
Measurement of chloride depends on the formation of 
insoluble silver chloride (AgCl) from chloride (Cl-) and 
silver (Ag+) ions. The total number of silver ions 
required to titrate the chloride is equivalent to the 
quantity of chloride present in a sample. The production 
of Ag+ ions at the silver electrodes generates an 
electrical current which is measured. 
b) Cytokines 
Tumour necrosis factor-alpha (TNF-alpha), Interleukin-! (IL-
1) and Interleukin-6 (IL-6) levels were determined by a solid 
phase ELISA (Quantikine human IL-6, IL-1 beta and TNF-alpha 
immunoassays by Research and Diagnostics systems purchased 
from British Bio-technology Limited). 
These assays employ the quantitative 'sandwich' enzyme 
immunoassay technique. All the samples were tested in 
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duplicate and a series of wells was prepared using known 
concentrations of IL-6, IL-1 and TNF-alpha standards. The 
range of concentrations for the IL-6 and IL-1 standards was 
2000 pg/ml, 1000 pg/ml, 500 pg/ml, 250 pg/ml, 125 pg/ml, 62.5 
pg/ml, 31.25 pg/ml, and O pg/ml. The range of concentrations 
for the TNF-alpha standards was 1000 pg/ml, 500 pg/ml, 250 
pg/ml, 125 pg/ml, 62.5 pg/ml, 31.3 pg/ml, 15.7 pg/ml and 0 
pg/ml. The appropriate diluent was used as the zero standard. 
Assay procedure 
( i) The microti ter plates were coated with a monoclonal 
antibody specific for IL-6, IL-1 or TNF-alpha. 
(ii) 200 µl of bile or standard was added per well and 
incubated for 2 hours at room temperature for IL-6 and 
IL-1 and at 37°c for TNF. If the samples contained any of 
the cytokines, they were bound by the immobilised 
antibody. 
(iii) Each well was then washed with 400 µl of wash 
buffer (Buffered Surfactant) to remove any unbound sample 
proteins. This washing procedure was repeated three 
times. 
(iv) Then 200 µl of 
against IL-6, IL-1 or 
peroxidase) was added 
'conjugate' (polyclonal antibody 
TNF conjugated 
to each well 
to horseradish 
and the plate 
incubated for 2 hours at room temperature for IL-6 and 
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IL-1 and at 37°C for TNF. This allowed binding of the 
conjugate to the cytokine which was bound during the 
first incubation. 
(v) The plate was then washed three times as in step 
(iii). 
(vi) 200 µl of 'substrate' solution (made from equal 
volumes of stabilised hydrogen peroxide and stabilised 
chromogen) was added to each well and the plate incubated 
for 20 minutes at room temperature. A colour developed in 
proportion to the amount of cytokine bound in the initial 
step. 
(vii) 50 µl of 'stop' solution (2 N sulphuric acid) was 
added to each well and mixed well. 
(viii) The optical density of each well was determined 
within 30 minutes using a spectrophotometer set to 450 nm 
and using dual wavelength correction (correction 
wavelength was 540 nm). This corrected for optical 
imperfections in the polystyrene microtiter plate. 
Sensitivity and specificity of the assay: Minimum 
detectable levels are 3.5 pg/ml for IL-6; 4.5 pg/ml for 
IL-1 and 4. 8 pg/ml for TNF-alpha. The assay is highly 
specific showing no cross reactivity with other 
cytokines. 
Bio-assays were not used because of the cytotoxici ty of 
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the bile salts and variable concentrations of 
cyclosporine present in bile samples. Bioassays are also 
not specific for individual cytokines. 
c) Porphyrin levels 
Porphyrin levels were measured by the Porphyria Laboratory, 
Medical School, UCT. Porphyrins were esterified with 
sulphuric acid in methanol, extracted with chloroform and 
then separated by thin layer chromatography. Amounts present 
were quantified by fluoroscanning and comparison with 
standard porphyrin solutions. 
6.3 RESULTS 
6.3.1 Biliary biochemistry 
The biochemistry results are expressed as medians and ranges 
except where the biochemistry of the individual patients is 
presented, in which case actual values are documented. 
a) Donor (controls) data 
TABLE 6.1. BIOCHEMICAL PARAMETERS IN DONOR BILE 
Median Range 
Total bilirubin 7200 3100 - 21200 µmol/1 
Alkaline phosphatase 520 200 - 1260 units/1 
Gammaglutamyl transferase 1070 340 - 6320 units/1 
Calcium 13.3 4.7 - 20.4 mmol/1 
Magnesium 9 2.7 - 10.7 mmol/1 
Sodium 346 208 - 408 mmol/1 
Potassium 14.4 10.2 - 21.4 mmol/1 
Chloride 108 0 - 246 mmol/1 
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Biliary biochemistry of 11 donors was analysed. The donor 
bile was obtained from the gallbladder and the levels of 
electrolytes (except for chloride which is lower) are 
normally higher than in T-tube bile (see Chapter 3). However, 
in these donors the slightly higher than usual Na+, K+, ca2+ 
and Mg2+ levels together with the high Cl - levels suggest 
possible cell membrane injury with alterations in membrane 
ion transport systems. The usual ranges for ALP and GGT are 
not known. 
The donor biliary biochemical parameters were then compared 
with those of T-tube bile obtained from the transplant 
patients. The values were compared at various time periods 
post transplantation (Day 1, Days 2-4, 5-8, 9-10 and 11-14) 
(see figures 6.1, 6.2, 6.3 and Table 6.2). 
Figure 6.1 BILIARY BILIRUBIN & ALP LEVELS 
POST TRANSPLANTATION 
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Figure 6.2 BILIARY CALCIUM & MAGNESIUM LEVELS 
POST TRANSPLANTATION 
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90 
Figure 6.3 BILIARY SODIUM, POTASSIUM & CHLORIDE 
POST TRANSPLANTATION 
(Results as medians) 
K+(mmol/1) • CHmmol/1) I d Na+(mmol/1) 
Controls 1 2-4 5-8 9-10 11-14 
(n•11) (n•2) (n•8) (n•13) (n•S) (n•8) 
Days 
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TABLE 6.2. BILIARY GGT AND ALP LEVELS POST TRANSPLANTATION 
Controls Day Days Days Days Days 
(n-11) 1 2-4 5-8 9-10 11-14 
(n=2) (n=9) (n=-18) (n=7) (n=B) 
GGT units/1 
Median 1070 551 194 268 480 566 
Range 340-6320 242-860 0-4530 6-1480 68-1242 264-2000 
ALP units/1 
Median 520 129 54 112 140 158 
Range 0-3000 68-190 0-650 20-1180 18-960 36-1118 
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As can be seen from the previous figures, the donor biliary 
biochemical parameters are higher than those of the 
transplant patients. Al though gallbladder bile is normally 
more concentrated than T-tube bile (higher ca2+, Mg2+, Na+, K+ 
levels), cell membrane injury may also have contributed to 
the higher levels. 
Biochemical parameters for the transplant patients were 
evaluated at the different time intervals previously stated 
in order to see whether any significant trends in changes of 
biochemical parameters could be related to clinical events 
such as rejection and infection. Day 1 values were separated 
from the rest as these values might still reflect the donor 
bile values. Rejection usually occurs between 4-10 days, 
therefore the Day 2-4 period was selected to detect pre-
rejection changes in biochemical parameters. The Day 5-8 and 
9-10 periods were chosen for early or late immune/rejection 
events. The Day 11-14 period might reflect the changes 
following administration of boosted immunosuppressive therapy 
or reflect changes relating to development of infection or 
cholestasis post-liver injury. 
At this stage, our number of transplant patients is still 
small and thus we were unable to group patients according to 
early or late rejection episodes. Thus evaluating changes in 
biochemical parameters at these time periods does not always 
accurately reflect 
patients (whether 
changes 
early or 
relating to rejection as 
late rejection occurred) 
all 
were 
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grouped together. However, there was a marked decrease in the 
biliary bilirubin levels prior to the usual time period for 
rejection, i.e. 4-10 days post-transplantation. The biliary 
ALP and GGT levels initially decreased in the first few days 
post-transplantation followed by an increase during the usual 
time period for rejection. 
It proved more useful to look at the biliary biochemical 
parameters of individual patients especially in those cases 
where serial bile samples were obtained. 
b) Individual patient data 
Serial bile samples were obtained from patients SS (OLTx 6), 
VT (OLTx 7) and AM (OLTx 8) and the biliary bilirubin 
parameters for these individual patients are presented in 
Figure 6.4. 
Figure 6.4 BILIARY BILIRUBIN LEVELS 
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When assessing individual patients, the biliary bilirubin 
levels proved a sensitive method of evaluating liver injury. 
The biliary bilirubin levels decreased in patients AM (OLTx 
8) and SS (OLTx 6) some time before clinical rejection was 
diagnosed. However, patient VT (OLTx 7) who had suffered a 
severe preservation injury, initially produced very little 
watery bile and only at Day 14 post transplantation did the 
biliary bilirubin levels start rising. Ultrasound of the 
liver and T-tube cholangiography excluded biliary obstruction 
in all three patients. A hepatic angiogram was performed on 
VT (OLTx 7) and excluded hepatic artery thrombosis. 
In the following graphs these patients' 
biochemical data is presented in more detail. 
individual 
Patient SS (OLTx 6) 
Figure 6.5 BILIARY BILIRUBIN AND ALP LEVELS 
POST TRANSPLANTATION 
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The biliary bilirubin levels decreased 3 days prior to the 
clinical diagnosis of rejection followed by a later rise in 
ALP. Within 24 hours of administering pulsed medrol, the 
biliary bilirubin levels begin to rise, reaching a plateau at 
Day 8 and then decreasing. 
Figure 6.6 BILIARY AND SERUM BILIRUBIN LEVELS 
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When comparing the biliary and serum bilirubin levels in 
relation to rejection, it can be seen that there is no 
significant change in the serum bilirubin levels prior to 
clinical rejection as opposed to the obvious marked decrease 
in biliary bilirubin levels (Fig. 6.6). 
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Patient VT (OLTx 7) 
Figure 6.7 BILIARY BILIRUBIN AND ALP LEVELS 
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VT (OLTx 7) suffered a severe preservation injury resulting 
in delayed graft function with prolonged cholestasis. 
Clinical rejection was diagnosed on Day 9 and pulsed medrol 
commenced. As can be seen from figure 7, following 
commencement of medrol, the biliary bilirubin levels begin to 
rise with a significant increase occurring at Day 14 (22-140 
µmol/1). There is a delayed rise in ALP associated with the 
diagnosis of rejection followed by a decrease in levels after 
administration of medrol. Liver biopsy was not possible 
because of haemostatic considerations. 
Figure a.a BILIARY AND SERUM BILIRUBIN LEVELS 
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Figure 8 compares the biliary and serum bilirubin levels in 
VT ( OLTx 7) . The serum bilirubin levels rise following the 
preservation injury and remain elevated, reflecting the 
consequent prolonged cholestasis. However, the biliary 
bilirubin levels remain low in the first 9 days in keeping 
with delayed graft function but following the administration 
of medrol for clinical rejection, there is a progressive rise 
in biliary bilirubin levels suggesting improvement in graft 
function. However, because of prolonged cholestasis and 
possible binding of bilirubin to albumin, there may be slow 
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clearance of serum bilirubin. The serum bilirubin levels thus 
do not reflect the possible early improvement in graft 
function. 
Patient AM (OLTx 8) 
Figure 6.9 BILIARY BILIRUBIN AND ALP LEVELS 
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The biliary bilirubin levels once again decrease 3 days prior 
to the clinical diagnosis of rejection followed by a delayed 
but less marked rise in ALP levels (Fig. 6.9). 
Figure 6.10 BILIARY AND SERUM BILIRUBIN LEVELS 
POST TRANSPLANTATION 
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In Figure 10, it can be seen that there is no significant 
change in the serum bilirubin levels in contrast to the 
marked drop in biliary bilirubin levels prior to rejection 
followed by a rebound rise in levels after administration of 
pulsed medrol. Liver biopsy taken at Day 30 revealed no 
evidence for further rejection. 
OLTx 11 suffered severe ischaemic injury and developed marked 
cholestasis. Serial bile samples were only obtainable 1 week 
post-transplantation and bilirubin levels in these samples 
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remained low (200-300 µmol/1). Liver biopsy confirmed 
extensive preservation injury with cholestasis. 
Biliary GGT levels initially appeared to decrease in the 
first few days post-transplantation followed by a rise during 
the usual time period for rejection (see Table 6.2). However, 
serial analysis of biliary GGT levels in individual patients 
(OLTx 6, 7, 8) did not show any consistent change in relation 
to rejection. 
6.3.2 Cytokines 
a) TNF-alpha and IL-1 
Biliary TNF-alpha levels were assayed in 5 donors and in the 
transplant patients (OLTx 2, 3, 4 and 6) and were 
undetectable. The IL-1 assay was performed on the same bile 
samples. IL-1 was detectable in three of the donor bile 
samples (median 56, range 0-73 pg/ml). One patient (OLTx 4) 
had an elevated level of 250 pg/ml on Day 8 post 
transplantation at the time of reactivation of Hepatitis B. 
IL-1 was undetectable in the other transplant patients even 
at times of rejection. 
As the biliary TNF-alpha and IL-1 levels did not appear to 
increase at times of rejection and in view of the expense of 
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these assays, these cytokines were not measured in subsequent 
donor and transplant patient bile. 
IL-6 is the major direct mediator of the hepatic acute phase 
response. IL-6 estimations were performed on all bile samples 
obtained from donors and transplant patients. 
Calculation of results: An average of the duplicate readings 
was taken. The zero standard optical density reading was 
subtracted from the sample optical density readings. The 
optical density for the standards versus the concentration of 
the standards was plotted. The data was linearised by log 
transformation and regression analysis was applied ( the r 
value was O. 997 for the IL-6 standard concentration curve, 
similar r values were obtained for the TNF and IL-1 standard 
concentration curve). 
TABLE 6.3. BILIARY IL-6 LEVELS POST TRANSPLANTATION 
IL-6 (range pg/ml) Median 
Controls (n=ll) 0-360 60 
OLTx 
Days 1 (n=2) 320-535 427 
2-4 (n=9) 0- 85 0 
5-8 (n=18) 0-158 44 
9-10 (n=6) 0-105 45 
11-14 (n=6) 0-192 14 
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IL-6 levels were high in donor bile and on Day 1 post-
transplantation. Although IL-6 levels appeared slightly 
elevated during the usual period of rejection (days 4-10), 
this was not significant and there was no increase in IL-6 
levels during the Day 2-4 period (see Table 6.3). Thus, IL-6 
did not appear to be a sensitive marker of rejection and this 
was confirmed when serial IL-6 levels were analysed in the 
individual patients SS (OLTx 6), VT (OLTx 7) and AM (OLTx 8) 
(see Fig. 6.11). 
Figure 6.11 BILIARY INTERLEUKIN-6 LEVELS 
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Elevated IL-6 levels were noted in OLTx 11 at times of 
biliary sepsis (192 pg/ml) and cytomegalovirus infection 
(1820 pg/ml). OLTx 3 had an elevated IL-6 level of 110 pg/ml 
associated with a cytomegalovirus infection. 
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Biliary bilirubin and IL-6 levels at the stipulated time 
periods were then compared (Fig. 6.12). As can be seen, there 
is a marked decrease in bilirubin levels but apart from the 
initial decrease in IL-6 levels after Day 1 ( this probably 
still reflects the high donor IL-6 levels). There are no 
significant changes in the IL-6 levels. 
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6.3.3 Porphyrins 
Porphyrins were measured in 7 donors and 5 transplant 
patients (OLTx 2, 3, 4, 6 and 7). Biliary porphyrin profiles 
were similar in donors and in the transplant patients ( see 
Table 6.4). 
TABLE 6.4. BILIARY PORPHYRIN PROFILE 
Coproporphyrin 
3-COOH 
Protoporphyrin 
Donors 
52% 
17% 
31% 
OLTx 
62% 
10% 
28% 
Bile contains large amounts of coproporphyrin which 
predominates over protoporphyrin. There is also a significant 
amount of 3-COOH porphyrin present in bile. This is the 
reverse of the normal faecal pattern. 
Serial biliary porphyrin analysis was only performed on two 
transplant patients (OLTx 6, 7). Interestingly, in OLTx 7 
(VT) who had experienced a severe preservation injury, the 
total porphyrin concentration was 219.5 nmol/1 on Day 1 and 
thereafter fell to undetectable levels and remained 
undetectable for the next 2 weeks. Patient SS (OLTx 6) had 
initially low levels following transplantation but after 
administration of medrol for clinical rejection, the 
porphyrin levels rose and then levelled off (see Fig. 6.13). 
Figure 6.13 BILIARY PORPHYRIN LEVELS 
POST TRANSPLANTATION 
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6.4 SUMMARY 
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It was thought that serial measurement of pro-inflammatory 
cytokines IL-1, IL-6 and TNF-alpha in bile might provide an 
early and sensitive marker for liver allograft rejection. 
However, this was not confirmed in our study. The measurement 
of biliary cytokines did not appear to predict rejection 
episodes. IL-6 levels were high in donor bile and then 
decreased rapidly. Isolated elevated IL-6 and IL-1 levels 
were associated with episodes of viral or bacterial 
infection. 
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However, serial biliary bilirubin measurements appeared to be 
a sensitive marker for liver injury. The biliary bilirubin 
levels decrease significantly prior to rejection and were 
very low in transplant patient OLTx 7, who experienced a 
severe ischaemic injury. 
These results, together with an overview, are discussed in 
more detail in Chapter 7. 
CHAPTER SEVEN 
Discussion 
7.1 INTRODUCTION 
Orthotopic liver transplantation has become established at 
Groote Schuur Hospital as the treatment of choice for 
selected patients with end-stage chronic liver disease. In 
some cases (OLTx 6 and OLTx 10), the post-operative course 
was uncomplicated, the patients being mobile within a few 
days and leaving hospital within 2.5 weeks of the operation. 
Others, however, had a stormy post-operative course 
complicated by severe rejection (OLTx 2, 5); infections 
(OLTx 9, 11); the consequences of preservation injury (OLTx 
7) or ischaemic injury with the development of biliary 
strictures and leak (OLTx 11). 
Cholestasis is a common post-operative problem and major 
aetiological factors include ischaemic/preservation injury, 
rejection, sepsis (bacterial, viral or fungal infections) 
and biliary anastomotic complications. It is not always easy 
to clinically distinguish rejection from other aetiological 
factors. The cause of cholestasis may be mul tifactorial. 
Rejection is often diagnosed once immunological processes 
have already become established. Thus, readily measurable 
biochemical or immunological parameters which could act as 
early specific and sensitive markers for rejection would be 
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a valuable clinical tool in the post-operative management of 
transplant patients. 
7.2 CYTOKINES 
These post-operative complications are associated with and 
influenced by the pro-inflammatory cytokines IL-1, TNF-alpha 
and IL-6. These pluripotential cytokines are produced by 
activated macrophages and mediate immunological responses 
and the acute phase reactions as discussed in Chapters 2 and 
5. IL-6 is of particular importance as a major and direct 
mediator of hepatic acute phase protein synthesis. 
Lymphocyte activation is an important early step in 
allograft rejection and the cytokines IL-Land TNF as well 
as IL-6 could play important roles in this regard. 
IL-6 has also been shown to have effects on cell-cell 
association and cell mobility in ductal breast carcinoma 
cell lines 60 • IL-6 decreases expression of the intermediate 
junctions which provide anchorage for actin microfilaments. 
These are responsible for maintaining the shape of 
microvilli and canaliculi 46 • Bile flow is facilitated by 
periodic contractions mediated by these microfilaments 53 • 
The intermediate junctions also serve as adhesive structures 
between cells. IL-6 also decreases the number of desmosomes 
which are responsible for protecting the cell membrane from 
deformation and damage due to distension. The loss of these 
'adherens' type junctions, i.e. intermediate junctions and 
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desmosomes results in decreased cell-cell contact60 , 
possible breakdown of tight junctions with loss of cell 
polarity. 
The loss of cell polarity may be associated with the 
redistribution of canalicular membrane transport carriers to 
the sinusoidal domain45 • 4 7, 54. 
Thus, IL-6 may contribute to the development of cholestasis 
with associated cytoskeletal changes. These may be central 
to intrahepatic (graft injury, rejection or hepatitis) or 
even extrahepatic (biliary tract strictures, anastomotic 
obstruction) cholestasis with ascending infection. 
IL-6 may through the alteration of cell contacts play a 
modulatory role in liver regeneration which may occur 
following hepatocyte necrosis in graft rejection or viral 
hepatitis. 
Serum soluble IL-2 receptor levels have been shown to rise 
prior to the clinical diagnosis of liver allograft 
rejection. Raised serum IL-2 receptor levels were not 
specific for rejection as they were also elevated in viral 
infections13 . Biliary soluble IL-2 receptor levels were also 
found to be elevated in liver allograft rejection and to be 
more specific and sensitive than elevated serum IL-2 
receptor levels14 . 
110 
IL-6 levels have been shown to be elevated in the serum and 
urine of renal transplant patients immediately post-
operatively. The levels then slowly decrease but increased 
again in association with acute rejection. The increase in 
IL-6 levels is more marked in urine12 • 
Serum TNF-alpha, IL-1 and interferon-gamma levels were found 
to be elevated in rejection but were not specific as they 
were also elevated in bacterial or viral infections120 • 
It was thought that measurement of the pro-inflammatory 
cytokines IL-1, TNF-alpha and IL-6, which are involved in T 
cell activation and the acute phase response might be 
sensitive markers for acute rejection. Moreover it was 
thought that biliary levels of these cytokines (the Kupffer 
cells of the liver are a source of cytokine production) 
might be more specific for rejection than serum levels which 
might also be elevated in systemic infection. 
In our study, the biliary IL-1 levels were slightly elevated 
in 3 of the 5 donors ( 7 3, 57 and 56 pg/ml) tested. Acute 
rejection was not associated with an elevation of IL-1 (OLTx 
2, 3, 4, 6). The only significantly elevated IL-1 level (250 
pg/ml) was associated with reactivation of hepatitis B viral 
replication on day 8 (OLTx 4). 
No detectable TNF levels were measured. This may be due to 
very low levels which were not detectable (unlikely in view 
of the sensitivity of the assay) or due to biliary TNF being 
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labile and therefore not measurable. Biliary IL-6 levels 
were markedly elevated in 4 of the 11 donors tested (360, 
359, 265 and 247 pg/ml). In the remaining 7 donors, the IL-6 
levels ranged between 0-89 pg/ml. These differences in the 
IL-6 levels in donor bile could relate to differences in 
cause of organic brain death (trauma, head injury or 
subarachnoid haemorrhage). 
Amongst the transplant patients, elevated biliary IL-6 
levels of 320 and 535 pg/ml were noted on day 1 in two 
patients (OLTx 6 and OLTx 8). Elevated IL-6 levels were also 
noted in association with biliary sepsis (192 pg/ml in OLTx 
11) and CMV hepatitis (110 pg/ml in OLTx 3 and 1820 pg/ml in 
OLTx 11). There were no significant reproducible increases 
in biliary IL-6 levels in association with early or 
established acute rejection. 
Thus, the elevated biliary IL-1 and IL-6 levels appear to 
reflect non-specific acute phase responses seen in organic 
brain death (i.e. the donors) as well as in viral and 
bacterial infections. The elevated IL-6 levels seen on day 1 
in two transplant patients probably still reflect the values 
of the donors as neither of these two patients had 
experienced significant preservation or ischaemic injuries 
and the levels had dropped to 85 pg/ml in one patient and 
were undetectable in the other patient on day 2. 
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There may be a number of reasons why the biliary cytokines 
particularly IL-6 were not elevated in acute cellular 
rejection. These could relate to: 
i) The presence of acute phase proteins which serve as serum 
carrier proteins: Alpha2-macroglobulin is one of the major 
plasma proteins43 •44 and levels may rise during acute phase 
responses. 
cytokines 
IL-644, 105. 
Alpha-2 macroglobulin binds to a number of 
including TNF-alpha44 •121 , IL-1 and 
This complex formation exerts effects on the 
distribution, bio-availability, stability and clearance of 
cytokines44 . The binding of alpha-2 macroglobulin with IL-6 
may protect IL-6 from the action of proteases, regulates the 
release of, and slows the rate of clearance of IL-6 from the 
circulation. Thus less IL-6 may be detectable in bile and 
urine during acute phase responses in which alpha-2 
macroglobulin is induced. 
Alpha-globulins have also been shown to decrease secretion 
of TNF by peripheral blood lymphocytes12 • Increased hepatic 
alpha-globulin production during acute phase response may 
suppress the cells which are secreting TNF, thus limiting 
lymphocyte activation121 • 
ii) Cytokine catabolism: The liver not only acts as a source 
of production but also as a scavenger of the cytokines IL-1, 
TNF-alpha and IL-6 85 • The liver is the major target organ of 
IL-6 106 • It has been shown that IL-6 binds to parenchymal 
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and non-parenchymal (mainly Kupffer cells) liver cells. IL-6 
is endocytosed, degraded, excreted into bile as degradation 
products in a rat model104 • There is also significant 
clearance of IL-6 by the kidneys. Interestingly, it has been 
shown in rats, that most of IL-6 after binding to the 
hepatocytes and inducing acute phase protein synthesis, is 
released from the hepatocyte membrane and transported to the 
skin where it is degraded107 • The situation in man is 
speculative. 
IL-1 is also cleared by the kidneys and TNF-alpha is cleared 
mainly by the liver, kidneys and spleen104 • Thus the liver 
is not the only site of clearance and degradation of 
cytokines. Biliary levels of these cytokines might not 
always reflect the increased levels of the cytokines 
associated with acute phase responses. 
iii) Immunosuppression and Glucocorticoids: Glucocorticoids 
act synergistically with the cytokines IL-1, IL-6 and TNF to 
cause induction of acute phase proteins. However 
glucocorticoids may also negatively downregulate IL-6 gene 
expression in inflammatory cells as well as inhibiting IL-1 
and TNF-alpha synthesis, thus helping to terminate the acute 
phase response by a negative feedback mechanism10 , 37 , 85 • 
Glucocorticoids also enhance IL-6 receptor expression103 and 
may thus enhance IL-6 binding to hepatocyte, uptake and 
degradation. 
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In addition to the endogenous glucocorticoids secreted 
during the acute phase response, transplant patients all 
receive maintenance immunosuppressive medrol as well as 
pulses of medrol at times of rejection. The exogenous 
together with endogenous glucocorticoids may thus enhance 
the negative feedback on cytokine synthesis, with the result 
that high biliary levels of cytokines might not be detected 
in rejection. 
Thus, in contrast to the study in rats where biliary IL-6 
levels were shown to rise with the progression of liver 
allograft rejection and then fall in the terminal stages of 
rejection122 , our study failed to show any significant rise 
in any of the biliary cytokines at times of rejection. This 
may relate to the fact that our patients are receiving high 
dose immunosuppressive therapy. Acute phase reactants and 
alpha-2 macroglobulin kinetics may be different in rats. It 
has been shown that alpha-2 macroglobulin mRNA induction by 
IL-6 may be 'sex-specific' in Wistar rats with only the male 
rats showing an acute phase response117 • 
7.3 BIOCHEMICAL PARAMETERS 
There was a significant, progressive diminution of bilirubin 
levels from 3 days before the clinical diagnosis of 
rejection. This was accompanied by a slightly later rise in 
the ALP. Moreover, the administration of medrol with 
clinical improvement of symptoms was associated with a 
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prompt rise ( often within 24 hours) of biliary bilirubin 
levels. Measurement of the electrolytes, calcium and 
magnesium did not show any particular trends in association 
with rejection. The levels of these parameters in donor bile 
was slightly higher than the usual gallbladder values, 
suggesting possible membrane injury associated with brain 
death in these donors. 
Interestingly, the porphyrins, obligate intermediates of the 
haem synthetic pathway, were found to be undetectable in 
patient OLTx 7. This patient had delayed graft function due 
to preservation injury. In another patient (OLTx 6), who was 
tested serially, porphyrin levels were shown to rise after 
treatment for rejection. The liver is the major source of 
haem synthesis and the production of porphyrins. Thus the 
low levels of porphyrin associated with graft dysfunction 
are quite compatible. Porphyrin levels in bile could be used 
as a marker of hepatic function. We are evaluating this 
possibility in more depth. 
7.4 SUMMARY 
Biliary cytokines did not prove to be useful and reliable 
markers of early rejection. The evaluation of these 
parameters has given valuable information and resulted in 
further avenues for research. The serial measurement of 
biliary 
decrease 
bilirubin levels show an early and 
a few days prior to rejection. 
significant 
The biliary 
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bilirubin levels were also a more sensitive marker of graft 
function than the serum bilirubin levels which did not vary 
significantly prior to rejection nor following the 
administration of medrol. 
Measurement of biliary bilirubin levels is a simple, 
inexpensive and non-invasive test. Serial measurements of 
biliary bilirubin although not specific, should prove useful 
in the early diagnosis of liver rejection in the correct 
clinical context. 
The data on the biliary cytokines in orthotopic liver 
transplantation has been accepted for presentation at the 
Ares Serano International Symposium on IL-6: Physiology and 
Clinical Potentials. Montreux, Switzerland - October 1991. 
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